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Urinary tract infections are common amongst infectious diseases in humans, and often these 
infections are caused by uropathogenic Escherichia coli. Effective antimicrobial treatment of 
infections are medical achievements that should not be taken for granted, as antimicrobial 
resistance has developed and causes treatments to become ineffective. Further, resistance 
traits can be spread between unrelated bacteria through mechanisms such as conjugation, 
where plasmids (mobile genetic elements) are potential carriers of multidrug resistance traits.  
Treatment strategies outside the production of novel antimicrobial drugs are being 
investigated. Collateral sensitivity is an example of a treatment strategy that specifically 
targets resistant bacteria. By gaining antimicrobial resistance to an initial drug, susceptibility 
towards other antimicrobials can increase due to the initial resistance. 
The aim of this project was to develop a homologous gene replacement approach to introduce 
or repair defined mutations known to cause ciprofloxacin resistance in Escherichia coli. This 
would enable investigation of the effects specific resistance-causing mutations have on 
collateral susceptibility changes in different strain backgrounds. Methods of traditional 
cloning by ligation, as well as the more modern isothermal cloning method, were used to 
build constructs that would replace the original genomic target by homologous gene 
replacement.  
While we were able to build gene constructs with defined mutations by isothermal cloning, 
moving these constructs into integrative plasmids for homologous gene replacement proved 
challenging. However, one construct was ligated into an integrative plasmid, but has yet to be 
transferred by conjugation to the clinical isolate of interest. Ultimately, we were able to 
design and optimize several cloning approaches to introduce or repair mutations, but further 
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Chapter 1: Introduction 
 
1.1 Escherichia coli  
 
Bacteria are broadly categorized into two groups, Gram positive bacteria and Gram negative 
bacteria. Gram positive bacteria have a cell wall consisting of a thick peptidoglycan layer, 
whereas Gram negative bacteria have a phospholipid bilayer membrane that surrounds a 
thinner peptidoglycan-containing cell wall. E. coli are Gram negative, unpigmented, rod-
shaped bacteria, and are defined as facultative anaerobes, because they grow optimally in the 
presence of oxygen, but have the ability to survive and still grow without oxygen. 
E. coli was discovered in 1885, and is a commonly studied microorganism. The genome of E. 
coli varies in size and the GC-content is approximately 50 % (1). There are about 4700 genes 
in the E. coli genome that originate from a gene pool with at least 10 000 different genes 
(after eliminating all transposable elements and prophages) (2). Of these genes, 2000 are 
found in all E. coli, representing the core genome. The remaining about 2700 genes of the 
accessory genome vary between different strains of E. coli. Among the 2700 accessory genes 
could be genes that for instance encode cellular changes that would make the bacterium 
resistant to certain antimicrobials.  
E. coli exist as a mutualistic contributor in our intestinal bacterial flora. But in addition to 
being a part of the normal bacterial flora in humans and many animals, some strains of E. coli 
are considered pathogenic, having the ability to cause disease. Large genetic diversity and 
changes in the accessory genome contribute to the broad spectrum of diseases caused by E. 
coli, including diseases that can vary from asymptomatic bacteriuria, to urosepsis and 
meningitis (3). Pathogenic E. coli can be grouped into several different pathotypes that 
commonly cause infection, e.g. enterotoxigenic E. coli (ETEC) and uropathogenic E. coli 





1.2 Urinary Tract Infections and Treatment 
 
Urinary tract infections (UTIs) are the most common infectious diseases in humans (4). They 
are most often caused by bacteria from the intestinal tract that enter the urethral opening and 
colonize the urinary tract (5). Uropathogenic E. coli (UPEC) is the most common cause of 
UTIs and is responsible for approximately 80% of uncomplicated UTIs (5). UTIs are 
categorized by severity and ascent of the infection up the urinary tract, ranging from 
asymptomatic bacteriuria (bacteria in the urine), to cystitis (infection in the bladder), to 
pyelonephritis (infection in the kidneys), and urosepsis (infection in blood). Women are more 
susceptible to UTIs than men; this is due to the shorter anatomic distance between the urethral 
tract and the anus, and the length of the urethral tract itself. Approximately 50% of all women 
will have a UTI during their lifetime, the majority are uncomplicated cystitis (5). 
The recommended treatment for a UTI varies with the severity of the disease, but there are 
several antimicrobial agents that are commonly used. For adults in primary care in Norway, 
trimethoprim, nitrofurantoin or pivmecillinam is prescribed for three days in cases of cystitis, 
while trimethoprim/sulfamethoxazole combination or pivmecillinam is prescribed for seven to 
ten days for treatment of pyelonephritis (6, 7). Ciprofloxacin (CIP) can be used in cases of 
pyelonephritis when initial treatment fails. However, the guidelines for antimicrobial 
treatment in Norway vary between the primary care and hospitals, where CIP is not used to 
treat pyelonephritis in hospitalized patients (8).  
Even though Norwegian guidelines for treatment of UTIs does not include CIP as first line 
treatment, CIP is frequently prescribed for other indications, such as lower respiratory tract 
infections and pneumonia (9). According to the Norwegian prescription registry 
(Reseptregisteret), 948 279 defined daily doses of fluoroquinolones were prescribed in 
Norway in 2010 (10).  
 
1.3 Antimicrobial Agents 
 
Antimicrobial agents are compounds that have the ability to kill or prevent the growth of 
microorganisms, such as bacteria. Antibiotics are naturally produced from microorganisms, 
for instance penicillin, which is produced by the fungi Penicillium chrysogenum (previously 
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known as Penicillium notatum) (11). Since antibiotics are also antimicrobials per definition, 
the term antimicrobial can be used when describing both naturally occurring and synthetically 
derived germicides.  
When antimicrobial drugs are used to inhibit or kill bacteria during the treatment of an 
infection, for the benefit of the patient, that antimicrobial should have a minimal effect on 
host cells. Ideally, antimicrobials have selective toxicity, where for example a specific 
antimicrobial drug target site is present in bacteria but is not found in mammalian cells. The 
antimicrobial would thereby only affect bacterial cells. Antimicrobials can be divided into 
groups based on the essential cellular processes that the drugs target as described in the 
sections below. See Figure 1 for illustration of common antimicrobial drug targets (and 
common mechanisms of resistance, which will be described in Section 1.4).  
 
 
Figure 1: Illustration of antimicrobial drug targets and mechanisms of resistance within a 
bacterium. The relevant drug classes are listed below each target and resistance mechanism. 





Inhibition of cell wall synthesis 
The function of the cell wall is to maintain the shape of the cell, and to delineate the cell from 
its outer environment while preserving osmotic pressure inside the cell (14). The cell wall of 
both Gram negative and Gram positive bacteria is composed of cross-linked peptidoglycan, 
which is a unique component in the bacterial cell wall (15). Synthesis of peptidoglycan 
molecules occurs in the cytoplasm. The peptidoglycan is then moved across the cytoplasmic 
membrane before assembly occurs by a transpeptidation reaction, where penicillin-binding 
proteins (PBPs) are responsible for the final steps of peptidoglycan crosslinking (15).  
ß-lactam antimicrobials (e.g. penicillins, cephalosporins and monobactams) possess 
similarities to a portion of the peptidoglycan structure that is bound by PBPs. ß-lactams act as 
competitive binders to PBPs and make a PBP-ß-lactam complex that is more stable than the 
naturally-occurring PBP-peptigoglycan complex. As a result, the transpeptidation reaction is 
irreversibly inhibited and peptidoglycan synthesis stops (14).  
Similarly, glycopeptides bind to the site of peptidoglycan that binds to PBPs, and thereby 
inhibit the formation of a PBP-peptidoglycan complex. In this way, glycopeptides prevent the 
incorporation of subunits to the growing peptidoglycan molecule. However, because of the 
size of glycopeptide molecules, Gram negative bacteria like E. coli are intrinsically resistant 
to glycopeptides (14), a phenomenon that will be discussed more in Section 1.4. 
Inhibition of folate synthesis 
Some components of bacterial folate biosynthesis are antimicrobial drug targets. However 
both prokaryotes and eukaryotes require folates and/or their cofactors for several important 
cellular and metabolic processes, including the synthesis of nucleotides, of which 
deoxyribonucleic acid (DNA) is build (16). Selective toxicity of antimicrobials towards the 
bacterial components of folate synthesis exists because folates are essential vitamins that 
humans do not produce on their own and must instead get from dietary intake, while bacteria 
have their own folate synthesis pathways (17). 
Sulfamethoxazole specifically inhibits the activity of dihydropteroate (DHP) synthase, an 
enzyme responsible for the production of 7,8-dihydropteroate from DHP and p-aminobenzoic 
acid (18). Trimethoprim inhibits the activity of dihydrofolate (DHF) reductase, which reduces 
dihydrofolate to tetrahydrofolate (18). Sulfamethoxazole and trimethoprim are antimicrobial 
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drugs often used in combination because they target different components in the same folate 
synthesis pathway, giving a synergistic antimicrobial effect. 
Inhibition of protein synthesis 
The production of proteins is a necessary process for any living organism, and proteins can 
serve as e.g. drug receptors, transporter molecules and regulators of gene expression. In order 
to synthesize proteins, active genes are used as a template where RNA polymerases transcribe 
the information from the gene into messenger-RNA (mRNA). The mRNA is then bound by 
ribosomes and translated; where a ribosome reads the code of the mRNA, transfer RNA 
(tRNA) carry amino acids to the ribosome, and a specific amino acid chain is assembled by 
the ribosome (19).  
Several components of protein synthesis in bacteria are drug targets for different groups of 
antimicrobials. The aminoglycosides, such as gentamicin, bind to specific proteins in the 30S 
ribosomal subunit. Further, they inhibit the binding of formylmethionyl-transfer RNA (fmet-
tRNA) to the ribosome, which is essential for protein synthesis to begin (15). Tetracyclines 
also bind to the 30S ribosomal subunit and prevent aminoacyl tRNA to associate with the 
ribosome (20). Other antimicrobials, such as the amphenicols, lincosamides, oxazolidinones 
and macrolides, bind to the 50S ribosomal unit, inhibiting assembly of the amino acid chains 
(15).  
Inhibition of nucleic acid synthesis 
Nucleic acid synthesis includes assembling deoxyribonucleotides and ribonucleotides to form 
DNA and RNA, respectively. The production of new DNA occurs by making a copy of one of 
the strands from the original DNA sequence, and enzymatically adding the complementary 
nucleotide bases (19). Inhibitors of nucleic acid synthesis have the ability to stop the 
production of DNA prior to cell division and prevent the transcription of RNAs through 
different approaches. Rifamycins binds to the RNA polymerase, blocking the synthesis of 
messenger-RNA (mRNA) (15). The quinolones, such as ciprofloxacin, inhibits DNA 
replication by targeting topoisomerases, which will be discussed further in the next section, as 




1.3.1 Ciprofloxacin – Mechanism of Action 
 
Ciprofloxacin (CIP) is a quinolone-class, synthetically-produced antimicrobial that is 
effective against a broad spectra of bacteria, which is reflected in its frequent use (21). CIP is 
an antimicrobial that inhibits DNA replication in bacteria by inhibition of specific 
topoisomerases, DNA gyrase (topoisomerase II) and topoisomerase IV (22). These 
topoisomerases are important for the correct unwinding of the DNA molecule before 
replication can proceed. Specifically, DNA gyrase is an enzyme that introduces negative 
superhelical turns into the positive superhelical DNA (22). DNA gyrase is composed of four 
proteins, two subunits of GyrA and two subunits of GyrB, which are encoded for by the gyrA 
and gyrB genes, respectively. Topoisomerase IV is an enzyme that removes the interlinking of 
daughter chromosomes, allowing segregation of the DNA into daughter cells at the end of cell 
division. Topoisomerase IV consists of two subunits of both ParC and ParE (22). CIP 
specifically blocks the activity of DNA gyrase and topoisomerase IV by stabilizing CIP-
enzyme-DNA complexes, which results in conformational changes to both the enzymes and 
the DNA (22). The CIP-enzyme-DNA complexes are reversible, but as they result in breaks in 
the double stranded DNA, the effect of CIP is considered bactericidal, as it induces killing of 
the bacteria. The absence of functioning DNA gyrase and topoisomerase IV would then 
inhibit replication and DNA repair processes within the bacteria (23). 
 
1.4 Antimicrobial Resistance 
 
Antimicrobial resistance (AMR) is a phenomenon where a microbe has the ability to survive 
antimicrobial action, and is no longer susceptible or inhibited by the antimicrobial drug. 
Determination of susceptibility is needed in order to identify bacteria as either sensitive, 
intermediate or resistant to specific antimicrobial drugs. According to “Helsebiblioteket”, a 
clinical definition widely used is that a bacterial strain is resistant when tolerating a 
concentration of an antimicrobial drug that is higher than the highest achievable drug 
concentration at the infectious site, indicating a high risk of therapeutic failure (24). 
Antimicrobial susceptibility can be expressed as the minimal drug concentration to inhibit 
visible bacterial growth, the minimum inhibitory concentration (MIC) (25). MIC values from 
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various bacterial populations of the same species can be used to inform clinical breakpoints – 
the specific drug concentrations where an isolate of this species usually is killed or growth is 
inhibited. Clinicians can use the clinical breakpoints to indicate dose sizes during 
antimicrobial drug treatment, but the breakpoints can also be used to determine if a strain is 
susceptible, intermediate or resistant when tested with antimicrobials in a laboratory. 
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) gathers MIC 
data from experiments done around the world. By collecting values from international studies, 
e.g. the ECO-SENS studies, they have produced graphs and tables displaying values of 
clinical breakpoints for specific strains in presence of antimicrobial drugs (26). From further 
analysis of this data they offer a public database with epidemiological cut-off (ECOFF) values 
which indicates the highest MIC value(s) within WT populations (27). This can be helpful for 
monitoring resistance development over large geographical areas. 
 
1.4.1 Detecting Antimicrobial Resistance 
 
There are several tests that can be performed on bacteria to determine their susceptibility 
towards antimicrobials. These include agar dilution, macro- and microbroth dilution, gradient 
strip diffusion (e.g. E-test®) and disk diffusion methods.  
Agar dilution is set up by making agar plates containing specific antimicrobial drug 
concentrations along a two-fold scale. Bacteria are then applied to the antimicrobial 
containing solid agar, and the MIC is the concentration in the plate where the drug inhibits 
bacterial growth (25). Similar to the agar dilution method, the macrobroth dilution is set up by 
making a gradient of antimicrobial drug concentrations, but in liquid broth instead of solid 
agar (25). An advantage to the agar dilution method is that several strains can be tested on one 
plate, while only a single strain can be added to a liquid culture. In the microbroth dilution 
method, a tray with typically 96 wells of ~200 µL is filled with broth containing 
antimicrobial(s), again at a range of drug concentrations. Using the tray of wells enables 
testing several strains on one tray, but the set up can also be several antimicrobial drugs that 




Also for testing the susceptibility towards antimicrobials, a bacterial strain can be spread on 
an agar plate, and disks or strips containing antimicrobial drugs can be added to the plate. For 
the gradient strip diffusion test, a plastic/paper strip containing an antimicrobial drug is 
applied to the plate with bacteria (25). The strip contains a drug-gradient that diffuses into the 
agar, and a scale is marked on the upper surface of the strip, making it possible to read the 
MIC where the bacteria stops to grow. Similarly, in the disk diffusion test, a paper disk 
containing the antimicrobial drug is applied to a plate containing bacteria. The disk has a 
specific drug concentration which creates a gradient in the agar as it diffuses into the medium 
(25). The disk diffusion method does not result in a MIC value, but inhibition of growth is 
analyzed by measuring the diameter of the inhibition zone (area around the disk where 
bacteria do not grow), relative to the time drug has diffused. The disk diffusion test can 
always be used as a qualitative measure of whether the bacteria is sensitive, intermediate or 
resistant, but also an approximate MIC can be calculated based on the result of the disk 
diffusion test (25). 
 
1.4.2 Mechanisms of Antimicrobial Resistance 
 
Some antimicrobial agents are naturally ineffective against particular bacteria; hence the 
bacteria are intrinsically resistant to the antimicrobial. An example is where Gram negative 
bacteria are intrinsically resistant to glycopeptides, since the glycopeptide-molecules are too 
large to efficiently move through the outer phospholipid membrane and reach its target, the 
peptidoglycan (28). Alternatively, some bacteria naturally lack the antimicrobial drug target 
completely, and therefore are not affected by the antimicrobial drug. This is the scenario with 
E. coli and the lipopeptide drug daptomycin, where E. coli lacks the drug target site in the 
cytoplasmic membrane (29). 
Contrary to intrinsic resistance, resistance can be acquired by bacteria, making previously 
useful antimicrobials ineffective. Common mechanisms of AMR can be grouped in three 
major categories; specific target mutations, enzymatic inactivation and general mechanisms, 
e.g. permeability modification (13). Specific mutations that alter the drug target, preventing 
the antimicrobial agent from binding or affecting the target, can cause resistance. Mutations 
can also occur in the promoter of a target, leading to an overexpression of the target, 
demanding an increase in antimicrobial molecules to be effective.  
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Some bacteria possess genes encoding specific proteins that can enzymatically modify or 
inactivate an antimicrobial agent; for example bacteria that produce the ß-lactam degrading 
enzyme, ß-lactamase (15). Finally, altering the membrane permeability, and thereby reducing 
the amount of drug that reach the cytoplasm, can cause resistance (13). This could happen 
either by reducing the uptake of drug into the cell, or by increasing the elimination of drug 





Resistance to CIP occurs in bacteria through two of the mechanisms mentioned above; 
alterations in the drug target and alterations in the membrane permeability (22). Mutations 
that encode for alterations to the drug targets, DNA gyrase and topoisomerase IV, are 
frequently observed. Mutations in gyrA are generally reported more often than in gyrB, while 
parC mutations have been found in clinical isolates of E. coli with high level of resistance and 
are more common than parE mutations (22). Often topoisomerase IV acts as a primary drug 
target in Gram positive bacteria, and DNA gyrase acts as the primary drug target in Gram 
negative bacteria. In E. coli, the DNA gyrase is more sensitive to quinolones than the 
topoisomerase IV, and mutations to DNA gyrase is common in CIP resistant E. coli (22). 
To have an antimicrobial effect, quinolones must enter the cytoplasm of the bacterium to 
reach DNA gyrase and topoisomerase. Quinolones enter through the cell membrane either 
through porins or by passive diffusion, which demands a high level of hydrophobicity in the 
drug (21). In E. coli and other Gram negative bacteria, there have been reported alterations in 
the number of porins in the outer membrane and increased expression of efflux pumps (22). 
This leads to reduced cytoplasmic concentrations of CIP, and decreased interaction between 
the antimicrobial drug and the drug targets.  
Efflux pumps, located on the cell membrane, can extrude CIP from the cell through energy-
demanding, active transport. Several efflux pumps have been characterized that efflux 
quinolones both in Gram positive and Gram negative bacteria (21). Previously reported 
mutations in E. coli have been shown to result in increased expression of efflux pumps like 
AcrAB-TolC, AcrEF-TolC, MdtK and EmrAB (30), (31). Efflux pumps are related to 
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multidrug resistance because efflux is not restricted to secretion of specific substrates. On the 
contrary, one efflux pump can be responsible for secretion of several antimicrobial drugs. For 
instance, the AcrAB-TolC efflux pump is known to efflux quinolones like CIP, but also other 
antimicrobials like tetracyclines, amphenicols, b-lactams and macrolides (30) (31). 
For CIP-resistant E. coli, individual mutations can increase the MIC by a factor of 2-20, but 
no single mutation alone can make the MIC rise above the clinical breakpoint (1 mg/L) (32). 
Resistance to CIP in E. coli is therefore a multistep process. 
 
1.4.4 Antimicrobial Resistance Development 
 
Bacteria that are fit and virulent can continue to colonize, grow and divide. However, the 
presence of antimicrobials puts pressure on bacteria by inhibiting essential cellular processes. 
To overcome this antimicrobial stress, there are several mechanisms that bacteria use to alter 
their genome and improve their likelihood of survival. Bacteria can obtain mutations in the 
already existing genetic material and/or acquire new genetic material by horizontal transfer 
between bacteria (33). 
A mutation is an alteration in the DNA, and a point mutation is a mutation where the 
alteration happens in a single base (34). Point mutations can be induced by mutagens, agents 
that are known to increase the mutation rate, or they can occur spontaneously. Mutations 
typically occur due to errors made during DNA replication. Normally, DNA polymerases 
have proofreading functions that greatly reduce the occurrence of point mutations. Point 
mutations include base substitutions (replacement of bases), base additions, and base 
deletions; and they can result in beneficial, neutral or harmful effects for bacteria (34).  
The functional consequences of base substitutions are either that the mutation changes a 
codon for an amino acid into another codon for the same amino acid (silent or synonymous 
mutation), that the mutated codon encodes a different amino acid (missense mutation), or that 
the mutated codon is a stop codon (nonsense mutation) (34). Base additions and deletions 
occur less frequently than base substitutions, but these mutations cause frameshifts that will 
result in an altered gene product (34). 
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Mutations resulting in a loss of protein function for the bacteria occur more often than 
mutations resulting in the gain of function (34). This illustrates the ability of bacteria to get 
rid of non-essential functions, and thereby increase fitness.  
When mutations occur in genes that are relevant for antimicrobial effect they could result in 
AMR. Mutation(s) in e.g. a gene that encodes for an antimicrobial target could result in an 
altered target making the bacteria more resistant to the antimicrobial. DNA mutations causing 
AMR may not occur simultaneously with exposure to an antimicrobial agent. In fact, 
mutations in genes that cause AMR can be present in bacteria without the bacteria ever being 
exposed to any antimicrobials in clinical use (e.g. penicillin-resistant strains of bacteria were 
detected before penicillin was introduced as a treatment (35)). Random mutations causing 
AMR are selected for by the presence of antimicrobials, and could then be maintained by 
bacteria. 
 
1.4.4.1 The Spread of Resistance 
 
Since the reproduction of bacteria occurs by division of one bacterial cell into two individual 
and identical cells, bacterial growth is considered to be exponential. A bacterium containing a 
resistance gene would “spread” the resistance trait by replicating; but in addition to this 
vertical gene transfer, transferring genes horizontally is possible amongst bacteria.  
Horizontal gene transfer (HGT) includes several genetic mechanisms that enable bacteria to 
receive and integrate new segments of DNA obtained from other bacteria. This enables the 
spread and exchange of resistance genes at a tremendous pace. The main mechanisms of HGT 
include transduction, transformation and conjugation of DNA and mobile genetic elements, 
such as plasmids (3). 
Through transduction, the transfer of DNA occurs via bacteriophages, viruses that are able to 
carry bacterial DNA. Bacteriophages infect host bacterial cells and are reproduced within the 
host. The bacteriophages package bacterial DNA, as well as their own, into capsids. The host 
cell eventually lyses, which enables the bacteriophages to infect new bacteria and transfer the 
bacterial DNA to a new host (3).  
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Transformation is the uptake and integration of free DNA-segments that are available from 
the environment around a recipient cell. The ability of E. coli to receive DNA by natural 
transformation is dependent on conditions in the environment, where successful 
transformation has been shown to be restricted to aquatic and calcareous habitats (36). E. coli 
can be made competent for transformation in the laboratory by treating the cells with 
chemicals like calcium chloride and heat shocking the cells, or by creating pores in the cell 
membrane using electrical pulses. 
Plasmids are small DNA molecules that exist within a bacterial cell but are separate from the 
rest of the chromosomal DNA. Plasmids replicate independently of the chromosomal DNA, 
and are capable of containing one or even several antimicrobial resistance genes, which can 
easily spread to many, unrelated bacteria (37). Mobile genetic elements, such as plasmids, are 
typically transferred by conjugation. Conjugative plasmids contain an origin of transfer, the 
oriT, which enables their transfer by conjugation. (33). Some plasmids have the ability to 
move between bacterial hosts that are distantly related.  
Conjugation is a process where DNA is transferred through direct contact between the donor 
and the recipient bacterial cell (38). The contact between the cells is by a pilus, produced by 
the donor cell, that attaches to the recipient cell and pulls it close. The double stranded DNA 
to be transferred is nicked at the oriT, and a single strand is received by the recipient through 
the pilus, which is followed by synthesis of the complementary strand in both the donor and 
recipient (38). After conjugation, both the donor and recipient carry the transferred DNA, and 
the recipient also gains the ability to produce pili and thereby becomes a donor as well. In 
addition to plasmids, other mobile genetic elements exist, and some are also capable of 
conjugation, but these are not relevant for this project. 
  
1.4.5 AMR – A Global Problem 
 
Multidrug resistant bacteria have evolved and are an enormous threat to modern medicine. To 
keep antimicrobial treatment effective as AMR has emerged, a shift towards the use of more 
broad-spectrum antimicrobials has been seen, at least in high-income countries (35). But as 
the latest generations of antimicrobials and broad-spectrum antimicrobials are increasingly 
ineffective due to AMR, we could be left with no effective antimicrobial drug treatments to 
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kill multidrug resistant bacteria, which can evolve further to become pan-resistant, or 
untreatable. Major surgery, organ transplantation, and treatment of premature babies are some 
of the medical achievements that would not be available without the ability to successfully 
treat bacterial infections (35). 
Continued overuse of antimicrobials over the last decades, both in the community, in 
hospitals, and in livestock animal farming and aquaculture, have contributed by putting 
evolutionary pressure on microorganisms to develop and maintain AMR (35). Antimicrobials 
are overused as prophylactics for prevention of infectious diseases in livestock farming and in 
aquaculture (39). This treatment method allows for animals to live under poor hygienic 
conditions but at the same time stay free of disease, and the constant antimicrobial pressure 
selects for AMR emergence in bacteria both within and around the animals (39). Also, in 
countries like India and China, antimicrobial contamination from drug production factories is 
a serious concern (40). Stricter manufacturing regulations could prevent antimicrobial waste 
from being dumped and spread in the environment.  
The pharmaceutical industry has not been able to develop enough novel antimicrobials needed 
to keep up with the rate of resistance development (35). Though novel antimicrobials are 
difficult to discover and develop, there are other strategies to extend the lifespan of the 
currently available and effective antimicrobial drugs. Improved guidelines for antimicrobial 
drug therapy and resistance surveillance have been established (41) and treatment approaches 
that could potentially reduce the selection for AMR are being explored in laboratories. 
Treatment approaches that have been tested in clinical trials include antimicrobial drug 
combinations, and drug cycling (42) (43). 
Another approach is to look for ways to specifically target resistant bacteria. For example, 
bacteria that have developed AMR to one specific antimicrobial drug have been shown to 
exhibit increased sensitivity towards other, unrelated antimicrobials as a result of the initial 
resistance. This phenomenon is known as collateral sensitivity (44). Choosing treatment based 
on collateral sensitivity could be an approach to effectively kill resistant bacterial populations 





1.5 Collateral Sensitivity 
 
Collateral sensitivity was first discussed by W. Szybalski and V. Bryson in 1952 in a study on 
cross resistance profiles of E. coli (44). They discovered that a resistant strain can show not 
only lower and equal, but also higher levels of susceptibility towards other antimicrobials not 
previously introduced to the strain. Cases where a resistant strain obtained increased 
sensitivity towards an antimicrobial, compared to the WT strain, were described as collateral 
sensitivity. If bacteria evolve to gain AMR during antimicrobial treatment of an infection, the 
treatment might be greatly improved by switching the therapy to a drug that the resistant 
strain is collaterally sensitive towards. The collaterally sensitive strain would then either be 
killed by the second drug, or could develop AMR to the second drug, in which case the strain 
would be reciprocally sensitive to the initial drug that was used (45)  
Maps of collateral networks have been made that show the collateral changes in sensitivity or 
resistance to a wide range of antimicrobials, resulting from an initial resistance to a specific 
antimicrobial (45) (46). The networks of collateral changes can be used to predict which 
antimicrobial(s) would be more effective in case a resistant pathogen evolves during the 
initial treatment of infection, and could suggest the secondary therapeutic choice. Based on 
these findings, new treatment strategies could emerge to improve some of the current 
guidelines for combination- and cycling therapy. The concept of collateral sensitivity could be 
helpful both to inform antimicrobial choice in the clinic and possibly reduce the need for 
development of novel antimicrobials.  
 
1.5.1 Collateral Sensitivity in Ciprofloxacin Resistant Mutants 
 
The collateral effects on antimicrobial susceptibility have been tested by members of the 
Microbial Pharmacology and Population Biology (MicroPop) research group (Podnecky et 
al., unpublished findings). Figure 2 shows a heat map of ten different CIPR strains and the 
fold changes in susceptibility to 16 different antimicrobial drugs. Their results showed that 
the collateral effects of the K56-2 CIP-resistant (CIPR) strain, differ from the K56-70 and 
K56-78 CIPR strains. K56-2 CIPR showed generally a lower frequency of collateral 
susceptibility changes to the tested drugs, than what is seen in the other nine CIPR strains. 
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K56-70 CIPR was similar to the majority of strains tested, while the K56-78 CIPR strain 
showed both high frequency and the highest levels of cross-resistance of the strains. The CIPR 
strains were whole genome sequenced to identify mutations that may cause CIPR. 
Interestingly, each of the K56-2 CIPR, K56-70 CIPR and K56-78 CIPR strains had the same 
amino acid substitution in GyrA, where the serine at position 83 was replaced with a leucine 
(S83L). This mutation is commonly observed in strains resistant to CIP (22). The K56-2 CIPR 
strain also had a second mutation in GyrA, where glutamic acid replaced the alanine at 
position 119 (A119E), as well as a mutation in ParC, where glycine at position 78 was 
replaced by aspartic acid (G78D). Thus, the K56-2 CIPR strain had mutations to both CIP 
drug targets, GyrA and ParC. Whereas, in addition to the GyrA S83L mutation, the K56-70 
CIPR and K56-78 CIPR stains had mutations that affect efflux pump expression. Both strains 
had mutations to the rpoB and marR genes, which affect expression of the MdtK and AcrAB-
TolC efflux pumps, respectively (30). Additionally, the K56-78 CIPR strain had a mutation in 
acrR, which another regulator of the AcrAB-TolC efflux pump.  
 
Figure 2: Heat map of Ciprofloxacin mutants and Collateral Changes.  The K56-2 CIPR strain 
(blue dot) shows differences in susceptibility to the K56-70 and K56-78 CIPR strains (blue arrows). 
Illustration is based on previous work done in the MicroPop lab where cross-resistance (red color) and 
collateral sensitivity (blue color) effects were observed. Abbreviations of antimicrobial drugs: AMX; 
amoxicillin, AZT; azithromycin, CAZ; ceftazidime, CHL; chloramphenicol, CIP; ciprofloxacin, COL; 
colistin, SXT; sulphamethoxazole/trimethoprim, ETP; erythromycin, FOS; fosfomycin, GEN; 
gentamicin, MEC; mecillinam, NIT; nitrofurantoin, TMP; trimethoprim, TEM; temocillin, TET; 




1.6 Homologous Gene Replacement 
 
Gene replacement by homologous recombination, or homologous gene replacement (HGR), 
can be used to genetically engineer bacteria, altering the genetic material to introduce a 
specific mutation or to insert or delete sections of DNA. The desired DNA construct, e.g. an 
experimentally modified gene containing defined mutations (also referred to as the HGR 
construct), is often inserted, or cloned, onto a integrative DNA vector that is used to move the 
HGR construct into the bacteria (47). The typical vectors used are plasmids, mobile genetic 
elements that carry genes and other genetic material (as described in Section 1.4.4.1). 
Through HGR methods, the desired construct, carried by the integrative vector, can be 
exchanged with a DNA segment in the bacterial chromosome, allowing the substitution of 
targeted genes with gene copies containing defined mutations (47). Gene replacement 
methods are used to investigate the specific effect of a gene or mutation, such as whether 
AMR to a certain antimicrobial and collateral effect changes towards other antimicrobials are 
due to specific mutations. 
In order for HGR to be successful, the DNA segments to be exchanged (the HGR construct 
and the genomic target) must have a high degree of similarity, or homology. Laboratory 
techniques allow for DNA modification of the construct, and short pieces of DNA can be 
added to an already isolated DNA fragment using PCR amplification or other molecular 
cloning approaches. In this way, regions of DNA that are homologous to the DNA 
surrounding the genomic target (homologous flanks) are added to the construct. Additionally, 
the bacteria must contain specific proteins that enable homologous recombination, amongst 
these proteins is RecA, which pairs homologous DNA segments and promotes the 
recombination event. 
The “in-out” method can be used for HGR in E. coli (47). In this method, the desired DNA 
construct is cloned into a conjugative and non-replicative integrative plasmid; e.g. the pEX6K 
plasmid (Figure 19). In addition to the desired construct, the integrative plasmid carries 
various genes that serve as selection- and counter-selection markers. For pEX6K, these 
include a kanamycin-resistance gene (nptII) as a selection marker and sacB, a gene that 




Figure 3: Illustration of Homologous Gene Replacement (HGR). The desired HGR construct is 
cloned onto an integrative plasmid. Homologous recombination (crossover event) occurs at one of the 
homologous flanking regions. Antimicrobial resistance selection causes maintenance of the plasmid 
integrate, creating merodiploids that contain both the HGR construct and the original genomic target. 
Resolution of the merodiploid (co-integrate) occurs by a second recombination event, where in one of 
two cases the original DNA genomic target is expelled together with the rest of the plasmid, leaving 
the desired construct in the chromosome. Illustration based on paper by Madyagol et al.,2011. (47). 
 
The lack of a compatible origin of replication in pEX6K forces bacteria that do not encode the 
pir gene (necessary for the R6K origin of replication, present on the pEX6K) to integrate the 
whole plasmid into the chromosome when exposed to kanamycin. This plasmid integration is 
mediated by homologous recombination at one of the homologous flanking regions. By 
selecting on kanamycin, the plasmid is maintained in the genome. With the integration of the 
plasmid DNA, the genome contains both the original genomic target and the desired HGR 
construct, making it a merodiploid (partial diploid). Additionally, the merodiploids contain 
the entire plasmid backbone and specifically, the sacB gene. sacB produces levansucrase, an 
enzyme that degrades sucrose and produces levans – fructose polymers of high molecular 
weight that are lethal to Gram negative bacteria (47). When exposed to sucrose, the counter-
selection forces the merodiploid to either mutate or get rid of the sacB gene, but because of 
the homologous regions in the DNA, another homologous recombination event typically 
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occurs. In the second recombination event, in one of two cases the recombination occurs at 
the second homologous region and the original genomic target is expelled together with the 
plasmid backbone. The plasmid is then recircularized, and the desired HGR construct is left in 
the chromosome. See Figure 3. 
 
1.7 Study Aims 
 
The aim of this project is to investigate the collateral differences in antimicrobial 
susceptibility between different strains of E. coli containing the same CIP-resistant (CIPR) 
mutation in gyrA and/or parC. We aim to develop an HGR approach to introduce or repair 
defined point mutations known to cause CIP resistance. HGR constructs of the gyrA and parC 
genes from the K56-70 WT and K56-78 WT strains containing the CIP resistance mutations 
from K56-2 CIPR, will be used to replace the original K56-70 WT and K56-78 WT genes, by 
homologous gene replacement. These cloned mutants will be studied by comparing the 
antimicrobial susceptibilities to those of the laboratory-selected mutants K56-70 CIPR and 
K56-78 CIPR. This will allow us to investigate what effects the resistance mutations have on 




My hypothesis is that when the K56-70 WT and K56-78 WT strains obtain the gyrA(S83L A119E) 
or parC(G78D) CIP resistance mutations from the K56-2 CIPR strain, the manipulated K56-70 
and K56-78 mutants will become CIP resistant, and will also adopt the collateral changes that 





2 Chapter 2: Material and Methods 
 
2.1 Bacterial Strains 
 
The clinical isolates used in this project are from community acquired UTIs in women, which 
have been collected and studied in the ECO-SENS project (48) (49). 
 
Table 1: Table of E.coli strains used in this project. 
Clinical	Isolates	
(ECO-SENS	 Year	 Country	 Phylogroup	 ST	
K56-2	 2000	 Greece	 B2	 73	
K56-70	 2007-2008	 Sweden	 B2	 550	














Vectors are used to carry genetic material. In this project, plasmid vectors were used, that 
were suitable for cloning with laboratory-modified genes. All plasmids used in this project are 






Table 2: Plasmid vectors and respective properties. 





pGEM®-T	Easy	 f1	ori	lacZ	AMPR	 3015	 Promega	(Wisconsin,	USA)	
pDS132	 R6K	oriV	oriT	CHLR	 5286	 Philippe	et	al.,	2004	(52)	
pEX6K	 R6K	oriT	sacB	KMR	 7298	 M.C.	Di	Luca,	unpublished	
 
2.3 Media Preparation and Growth Techniques 
 
All cultivation of bacteria in this project included growth of the bacteria in ambient air at 
37°C overnight, unless otherwise specified. 
 
2.3.1 Solid Growth Media 
 
Generally, media for solid cultivation was prepared by mixing nutrient-rich powders, e.g. 
Luria Bertani (LB) broth powder, with agar and distilled water (dH2O) in a Pyrex bottle. The 
recipes used in this project are listed in Table 3. Solutions were then sterilized by autoclaving 
at 121 °C for 20 minutes. Media was cooled to about 50 °C on a magnetic stirrer, then poured 
into Petri plates. After solidification at room temperature, the plates were stored at 4 °C. 
When necessary, chemicals such as antimicrobial drug(s) were added to the media just before 
pouring the plates. See Table A 1 in Attachments for antimicrobials and respective 




















2.3.2 Plating of Cells on Solid Growth Media 
 
Spread plating was used to get even growth across an entire plate. When spread, bacterial 
solutions were pipetted onto plates with solid media and a sterile plastic T-shaped spreader 
was used to spread the cells evenly on the whole surface of the plate, before inverting the 
plate and leaving it for incubation. 
To purify bacterial isolates, the “streak for isolation” method was used to obtain single 
colonies. A sterile plastic loop was used to touch e.g. a colony growing on a plate or collect a 
small amount from a freeze culture. The bacteria-containing loop was used to streak the 
bacteria onto a plate by rapidly moving the loop back and forth, covering about one third of 
the plate (zone one). A new loop was used to streak from the inoculated area of zone one, 
onto approximately another third of the plate (zone two). The loop was then turned over and 
the clean side was used to streak from zone two onto the rest of the plate (zone three) in a zig 
zag pattern. 
 
2.3.3 Liquid Growth Media 
 
For preparation of liquid media used to grow overnight cultures, 5 mL of liquid LB (general 
lab supply) was added to a round bottom tube with a vented cap. If the media contained 
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additional chemicals, such as antimicrobial drug(s), this was added to the media just before 
inoculation. See Table A 1 in Attachments for antimicrobials and respective concentrations 
used in preparation of selective media in this project. The bacteria added to the media was 
either from a glycerol freeze stock, or a single colony picked from an overnight culture 
growing on solid media. Liquid cultures were placed in a shaking incubator at 225 revolutions 
per minute (rpm). 
 
2.3.4 Preparation of Glycerol Freeze Stocks 
 
0,5 mL of an 80% glycerol solution was added to a screw capped cryotube. 1,5 mL of a liquid 
overnight culture of the desired bacteria was mixed with the glycerol to give a 2 mL freeze 
stock with a final glycerol concentration of 20%. Freeze stocks were stored at -75 °C. In this 
project, freeze stocks were made after every successful transformation of genetic material into 
a recipient strain. 
 
2.4 Isolation of Genomic DNA 
 
For isolation of genomic DNA from E. coli, the GenElute Bacterial Genomic DNA Kit 
(Sigma Aldrich, Missouri, USA) was used according to the manufacturer’s guidelines. A 5 
mL liquid culture with the desired bacteria was grown overnight. 1,5 mL of the liquid culture 
was centrifuged for two minutes to form a pellet of the bacterial cells. The supernatant was 
discarded, and the pellet was re-suspended thoroughly in 200 µL of lysozyme (100 mg/mL) 
before incubation at 37 °C for 30 minutes. To degrade RNA, 20 µL of RNase A (10 µg/mL) 
was added, followed by incubation at room temperature for two minutes. 20 µL of proteinase 
K (20 mg/mL) and 200 µL of lysis solution C was then added. The sample was vortexed for 
about 15 seconds (secs) and incubated for 10 minutes at 55 °C. This resulted in lysis of the 
cells and degradation of proteins.  
The columns provided in the kit were prepared by adding 500 µL of column preparation 
solution and centrifuging for one minute. To prepare the DNA to bind to the column, the 
DNA was dehydrated by adding 200 µL of 95-100% ethanol (EtOH), followed by vortexing 
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of the sample. The entire sample was then transferred to the column, and centrifuged for one 
minute. The DNA that had bound to the column was washed twice by adding 500 µL wash 
solution, followed by centrifugation steps of one and three minutes (respectively). After the 
second wash, the column was centrifuged for one additional minute, to make sure all of the 
residual EtOH was removed. The column was then placed in a clean collection tube and 100 
µL of Tris-buffer (10 millimolar (mM)), was added to the center of the column and incubated 
at room temperature for five minutes. The DNA and buffer were eluted into the clean 
collection tube by centrifugation for one minute. All centrifugation steps were carried out at 
13 000 rpm. Genomic DNA was stored at 4 °C. 
 
2.5 Plasmid Isolation 
 
Plasmid DNA was isolated from bacterial cells using the GeneJET® Plasmid MiniPrep Kit 
(Thermo Fisher Scientific, Waltham, USA), following the manufacturer’s guidelines. 
Typically, a 3,5-5 mL liquid culture of the cells containing the plasmid of interest was grown 
overnight in LB, with an antimicrobial drug added for selective pressure (Table A 1). The cell 
suspension was pelleted and re-suspended in 250 µL resuspension buffer; then the cells were 
lysed with 250 µL lysis buffer. The lysate was neutralized by addition of 350 µL 
neutralization solution, and the cell debris was pelleted during a 5-minute centrifugation step. 
The supernatant containing the plasmid DNA was applied to a silica column, and was then 
centrifuged for one minute, binding the DNA to the column. After adherence to the column, 
500 µL of the EtOH-containing wash buffer was added to remove remaining impurities from 
the DNA sample and centrifuged for one minute. The wash step was repeated a second time, 
and then the empty column was centrifuged for an additional one minute to remove any 
residual EtOH. The pure DNA was eluted into a sterile tube with a small volume, typically 30 
µL, of elution buffer. All centrifugation steps were carried out at 13 000 rpm. Plasmid DNA 
was stored at -20 °C.  
In some cases, we suspected bacteria contained a low copy number of plasmids, which 
resulted in low plasmid yields after isolation. In these cases, six replicates of 5 mL liquid 
cultures were prepared, and treated as single plasmid isolations through cell lysis, 
neutralization and pelleting of the cellular debris. The supernatant of the six replicates were 
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then bound onto one silica column, and the plasmid isolation was completed as described 
above.  
In some occasions during this project, the kit was not available in the lab, and in those cases 
the Monarch® Plasmid Miniprep Kit (New England Biolabs (NEB), Massachusetts, USA) 
was used, according to the manufacturers protocol. 
 
2.6 Quantification of DNA 
 
For quantitating DNA in this project, the NanoDrop™ 1000 Spectrophotometer (Thermo 
Fisher Scientific) was used, an instrument that is based on UV/VIS spectrophotometry. After 
nulling the instrument with sterile Milli-Q water, 1,5 µL of a DNA sample was placed 
between the two pedestals on the instrument. A xenon flash lamp illuminated the sample and 
a spectrometer analyzed the light that passed though. According to Beer’s law, the 
concentration of the analytic agent in a sample is proportional to the absorbance of light. 
Before analyzing DNA samples, the instrument was initialized by adding the sample 
background to the instrument as a blank. The sample background was typically elution buffer. 
In this way, only the absorbance of light by the analytic agent itself, in this case the DNA, 
was accounted for when determining the concentration.  
The spectrometer takes measurement at several wavelengths (ranging from 220-750 nm), 
which assesses the purity of the sample. Contaminants, like proteins or phenols, will absorb 
strongly around 280 nm while DNA is detected at 260 nm. The purity of a DNA sample is 
measured as the ratio of absorbance at 260 nm and 280 nm, the 260/280 ratio. For pure 
samples this value should range from about 1,8-2,2, where lower values indicate impurity. 
 
2.7 Restriction Endonuclease Digestion 
 
After insertion of a DNA segment into a plasmid vector by ligation, the plasmids were cut 
with restriction endonucleases, which are enzymes that cut double-stranded DNA at specific 
recognition sites. The resulting DNA digest sizes could indicate the content of the plasmid, 
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and tell whether a segment had been inserted or not, and sometimes the orientation of the 
insert.  
DNA digests were setup according to the recipe in Table 4, and were incubated at the 
appropriate temperature, typically 37°C, for one hour. The DNA fragments after digestion 
were analyzed by electrophoresis (Section 2.9), and the sizes of the fragments were used 
confirm successful ligation of the DNA segments. See Table A 4 in Attachments for 
restriction endonucleases and the corresponding buffers used in this project.  
 







In some cases, sequential digests were set up, where several endonucleases were added one 
after another to one digestion reaction that was incubated at different temperatures for each 
enzyme.  
Restriction endonucleases were also used for cloning itself, see Section 2.12.4. 
 
2.8 Polymerase Chain Reaction 
 
Polymerase chain reaction (PCR) is a method to amplify a specific piece of DNA. The 
method is based on using the piece of DNA to be amplified, also known as the amplicon, as a 
template for the production of new DNA copies, in a reaction that includes specific enzymatic 
reagents and temperature shifts. 
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After a mixture of the needed reagents, often called a PCR master mix, is prepared, the 
reaction occurs repeatedly in cycles using a thermal cycler, which allows rapid and controlled 
shifts of temperature. At temperatures around 93-98 °C, double stranded DNA reversibly 
denatures into two single, complementary strands. At lower temperatures, when the template 
DNA is still present as two single strands, short segments of DNA that are complementary to 
specific sites of the single strands, can anneal. These short DNA segments are known as 
primers, and will anneal to complementary single stranded DNA at temperatures around 50 
°C (or 5 °C below the specific primer’s melting temperature). A set of two primers is 
necessary, binding both strands of the amplicon. After primer binding the temperature rises to 
68-72 °C, so that the DNA polymerase enzyme can generate a new copy of DNA. The DNA 
polymerase incorporates deoxynucleotides (dNTPs) that are complementary to the single 
strand, thereby synthesizing a new double stranded piece of DNA. After the synthesis of the 
new DNA, the temperature is again risen to 93-98 °C, making also the newly synthesized 
DNA available as single stranded templates. This makes the reaction exponential.  
All the reagents used to make a master mix of one PCR reaction are listed in Table 5. The 
following thermal steps were used: initial denaturation at 98 °C for 30 secs followed by 30 
cycles (98 °C for 10 sec; 59,7-64 °C for 30 sec; 72 °C for 30 secs per kilo base pair (kbp) of 
amplicon) and a final extension at 72 °C for 10 minutes.  
 




5X	Phusion	High	Fidelity	buffer	 5X	 5	µL	 1X	
dNTP	 10	mM	 0,5	µL	 0,2	mM	
Forward	Primer	 10	µM	 1	µL	 0,4	µM	
Reverse	Primer	 10	µM	 1	µL	 0,4	µM	
Phusion	High	Fidelity	DNA	
polymerase	 2000	U/mL	 0,5	µL	 1	U/reaction	
DNA	template	 		 1-1,5	µL	 		




2.8.1 PCR Primer Design 
 
A primer is a short sequence of nucleotides that is needed to amplify specific DNA segments 
during PCR. The freeware program Primer3 (53) was used to design the primers, but some of 
the standard parameters were specified in order to optimize the primers.  
The primers, preferably between 18 and 23 bases in size, were not to contain four or more of 
the same nucleotide in a row. The melting temperature of the primer should be between 57 
and 62 °C, and a content of the bases guanine (G) and cytosine (C) of around 50% was 
optimal. Also, the 3´ ends were to include a G or a C base, which made the primer bind 
tightly to the C or G base in the complementary strand. Having a G or a C at the 3´ end is 
known as a GC-clamp, and this is preferable because there are three hydrogen bonds between 
a G and a C base, whereas there are only two hydrogen bonds between a thymidine (T) and an 
adenine (A). A GC-clamp aids the DNA polymerase to begin adding the bases needed to 
make a complete double strand.  
The primers were always designed to be complementary to parts of the desired amplicon(s), 
but in cases where PCR products were used for cloning by ITAC, primers were designed to 
also include a 5´ region (30 bp) complementary to the overlapping parts of the fragments to be 
cloned. (See Section 2.12.3) All primers are listed in the oligonucleotide Table A 3 in 
Attachments. 
 
2.9 Gel Electrophoresis 
 
For analysis of DNA fragments in this project, gel electrophoresis was used. The method is 
based on loading a DNA sample on a gel, and then providing electrical current which makes 
the negatively charged DNA wander from a negatively charged pole to one of positive charge. 
To keep the DNA samples from floating up and out of the gel, a loading buffer that weighs 
down the samples was always added. Different fragments of DNA were separated from each 
other by size, since smaller fragments travel easier through the gel matrix than larger ones. 
Different gels can be used for this purpose, but in this project only agarose gels were used.  
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In order to visualize the DNA on the gel, ethidium bromide (EtBr) was added to the gel, 
which intercalates between base pairs in the DNA. EtBr is visualized by exciting it with UV-
light, this is a way to monitor the DNA segments as they move across the gel. A DNA ladder, 
a mixture of DNA fragments of known sizes and concentrations, was added to every gel as a 
comparison to the samples. Figure A 1 in Attachments shows the DNA ladder used, 
SmartLadder MW-1700-10 (Erogentec, Seraing, Belgium). 
Typically, a 1% agarose gel was made with 0,5 or 1 g agarose powder (Invitrogen) solubilized 
in 50 or 100 mL, respectively, of 1X Tris-acetate-EDTA (TAE) buffer at the boiling 
temperature of the buffer. Occasionally, when analyzing PCR products of small size, a 2% 
agarose gel was prepared to increase the separation of small DNA fragments through the gel. 
Before casting, the gel-solution was supplemented with EtBr to a concentration of 0,3 µg/mL. 
Both 1% and 2% agarose gels were run at 100 volt (V) for one hour.  
 
2.10 Gel Extraction 
 
In order to keep and continue working with DNA samples that have been analyzed by gel 
electrophoresis, DNA was extracted from the agarose gel. The QIAquick® Gel Extraction Kit 
(Qiagen, Hilden, Germany) was used.  
The gel extraction procedure included cutting the desired DNA band out from the agarose gel 
and dissolving the gel slice in 3 volumes equivalents of a pH-adjusted buffer at 50 °C. 
Isopropanol (100%) (one volume equivalent) was then added to the dissolved sample. The 
sample was applied to a silica column followed by one minute of centrifugation. DNA 
binding of the sample to the column occurred at a pH ≤ 7,5. 750 µL wash buffer was then 
added to remove other components from the column. The wash buffer and contaminants were 
removed by centrifuging the sample twice, and finally the purified DNA was eluted from the 
column using 30 µL of elution buffer that had been preheated to 42 °C. After addition of the 
buffer, the sample was incubated at room temperature for five minutes before centrifugation 
for one minute to elute DNA. 
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In some occasions during this project, there was doubt about the efficacy of this gel extraction 
kit, and in those cases the Monarch® DNA Gel Extraction Kit (NEB) was used according to 
the manufacturer’s protocol. 
 
2.11 DNA Sequencing 
 
With DNA sequencing, the order of nucleotides within a DNA fragment is determined. In this 
project, Sanger sequencing with the BigDye® Terminator v3.1 Cycle Sequencing Kit 
(Thermo Fisher Scientific) was used.  
To prepare the DNA to be sequenced, a 20 µL sample (Table 6) of the template DNA, 
primer(s) to amplify the template, BigDye v3.1, 5X buffer and sterile Milli Q water, was run 
in a ThermoCycler for the following reaction: 96 °C for 1 min, followed by 25 cycles of 96 
°C for 10 secs; 50 °C for 5 secs; 60 °C for 2 minutes. After preparation, the samples were sent 
to be sequenced at the Medical Genetics Department at the University Hospital of North 
Norway. The results were analyzed using the Sequencher DNA Sequence Analysis Software 
(Gene Codes Corporation, Michigan, USA). 
 
















2.12 Molecular Cloning 
 
2.12.1 Zero Blunt® PCR Cloning  
 
The pCR®-Blunt plasmid vector from the Zero Blunt® PCR Cloning Kit (Invitrogen) was 
used for subcloning of DNA fragments. Successful insertion of a DNA fragment into the 
pCR®-Blunt plasmid (Figure 4) disrupts expression of the lethal lacZa-ccdB gene fusion, 
which results in death of transformants containing the plasmid without a DNA insert. See 
Table 2, for description of pCR®-Blunt plasmid features.  
 





The 10 µL ligation reaction consisted of the pCR®-Blunt plasmid, the blunt ended PCR 
product to insert, DNA ligase to fuse the fragments together, in addition to buffer and water. 
See Table 7. 
 








A 1:10 molar ratio of vector:insert was used. The amount of PCR product DNA added in the 








The ligation reaction was incubated at room temperature for one hour, then stored at 4 °C 






2.12.2 pGEM®-T Easy Cloning  
 
The pGEM®-T Easy vector (Figure 5) from the pGEM®-T Easy Cloning Kit (Promega) is a 
linearized plasmid with an additional T base on both 3´ ends, also known as T-overhangs. 
DNA fragments with T-overhangs in the 3´ ends can be ligated with DNA fragments 
containing an additional A base, so called A-overhangs, in the 5´ ends. For attachments of the 
fragments, DNA ligase makes covalent phosphodiester bonds between the hydroxyl and 
phosphoryl ends of the DNA fragments and hydrogen bonds are generated between the T and 
A nucleotides, thereby creating a new base pair (54). Hence, for successful ligation into the 
pGEM®-T Easy vector, the inserts must contain an A-overhang in the 5´ ends (see next 
section). See Table 2 for pGEM®-T Easy plasmid properties.  
 
Figure 5: Plasmid map of pGEM®-T Easy (3015bp). Properties and restriction sites used in this 




A 10 µL ligation reaction (Table 8) was used to fuse the pGEM®-T Easy vector with the 
constructs that contain an A-overhang. After incubation at room temperature for one hour, the 
reaction solution was stored at 4 °C overnight, and transformed into chemically competent E. 
coli DH5-a the following day (Section 2.13). When plated on LB and 5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside (XGal) and isopropyl b-D-1-thiogalactopyranoside (IPTG), 
transformants containing plasmids with the inserted sequence will be white. Transformants 
carrying an empty vector will be pigmented blue (known as blue/white screening). 
 









2.12.2.1 Synthesizing 5’ A-overhangs 
 
To create an A-overhang on the 5´ ends of blunt-ended PCR products, A-nucleotides had to 
be attached to the ends. In this project, a 10 µL reaction was set up by mixing 5 µL of the 2X 
DreamTaq™ master mix, containing the DreamTaq™ polymerase (Thermo Fisher Scientific), 
with 3 µL PCR product and dATPs to a final concentration of 0,2 mM. The sample was 
incubated at 70 °C for 30 minutes, which allowed the polymerase to modify the DNA ends 
and attach the A-overhang. DNA polymerases with good proofreading functions, such as the 
Phusion High-Fidelity DNA polymerase (used for PCR amplification in this study), will see 




2.12.3 Isothermal Assembly Cloning 
 
Isothermal Assembly Cloning (ITAC), also known as Gibson Assembly cloning, is a single-
step method of molecular cloning that combines DNA fragments that contain overlapping 
regions (55). In contrast to traditional cloning, the shape of the fragment ends is irrelevant for 
ITAC. However, for the fragments to be successfully combined, the ends must contain 
identical, or so called overlapping, regions of 15-80 bases, see Figure 6.  
ITAC involves several steps to process and combine the DNA fragments. First the 5´ T5 
exonuclease digests into the 5´ ends of both the double stranded insert and vector. This 
enzyme is only active after adding the DNA fragments to the master mix and until the 
incubation at 50 °C, which inactivates the exonuclease. The exonuclease digestion creates 
single stranded 3’ overhangs. Exposing the single stranded DNA allows the complementary 
ends of the DNA fragments to anneal. The High Fidelity DNA polymerase then incorporates 
dNTPs to fill in the gaps that might have occurred, before ligation by T4 DNA ligase, which 





Figure 6: Illustration of ITAC reaction. Two double stranded DNA fragments with identical 
(overlapping) regions are added to the ITAC master mix followed by an isothermal reaction at 50°C. 
The thermosensitive enzyme exonuclease digests on 5´ ends, making complementary single stranded 
3´ overhangs in the fragments. Exonuclease gets inactivated and the fragments anneal where 
polymerase fills the gaps. Finally, DNA ligase attaches the fragments. Illustration is based on paper by 
Gibson et al., 2009 (55) and protocol description from NEB (56). 
 
The DNA fragments to be combined (vector and insert) were amplified by PCR. PCR primers 
for ITAC were designed with regions that were complementary to the desired amplicon 
(about 20 bases) and also complementary to the DNA fragment that it would be combined 
with (30 bases). The amplified segments therefore contained an addition of 30 bases on the 5´ 
end of the final PCR products, representing the overlapping region.  
A total volume of 5 µL of the two PCR products were added to 15 µL of the ITAC master 
mix (Table 9), which contains the following enzymes: 5´ T5 exonuclease, DNA polymerase 
and DNA ligase. Reactions were incubated at 50 °C in a thermocycler for one hour. ITAC 
reactions were then transformed into chemically-competent E. coli with appropriate selection 









5X	ITAC	Buffer	 5X	 320	µL	 1,33	X	
T5	Exonuclease	 10	U/µL	 0,64	µL	 6,4	U	
Phusion	DNA	polymerase	 2	U/µL	 20,0	µL	 40	U	
Taq	DNA	Ligase	 40	U/µL	 160,0	µL	 6400	U	
Sterile	Milli-Q	Water	 		 Ad	1200	µL	 		
 
2.12.3.1 Drop Dialysis 
 
DNA samples were purified using sterile Milli-Q water by a method known as drop dialysis. 
The DNA sample was spotted onto the surface of a filter-paper with 0,05 micrometer (µm) 
pores, that was floating on the water. Typically, an empty petri plate was used for this 
purpose, and the sample was incubated at room temperature for 20 minutes. The goal was the 
removal of excess salts and other leftover substances remaining from previous reactions, such 
as the ITAC master mix.  
 
2.12.4 Cloning with Restriction Endonucleases 
 
DNA digestion of both vector and insert DNA with the same or compatible restriction 
endonucleases leave ends of the fragments that are complementary to each other, and can be 
cloned together by DNA ligation. However, this method requires a dephosphorylation step, 
preventing the plasmid from recircularizing without the desired insert, see next Section. (See 
Section 2.7 for restriction endonucleases used in plasmid identification.) 
A 20 µL reaction containing 1 µL T4 DNA ligase (Promega), 5X Ligation buffer (4 µL), 
vector and insert DNA, and sterile Milli-Q water, was incubated at room temperature for one 
hour. After incubation, the sample was stored overnight at 4 °C before transformation into 
chemically competent E. coli DH5-a.  
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A molecular ratio of 1:1 represents a scenario where there is one vector for every one insert. 
The ratios between vector and insert were calculated based on the following equation:  
(6,02	x	109F)	(DNA	 ng/µL 	x10CR)
(Size	 bp )	(660) = copy	number/µL 
copy	number/µL
(6,02	x	109F)	(10*:) = fentamoles/µL 
 
Copy number/µL represents how many copies of the vector or insert is in one µL of DNA 
sample. For the ligations, 15 fentamoles of the vector and 45 fentamoles of the insert (1:3 
molar ratio) was used. 
 
2.12.4.1 DNA Dephosphorylation 
 
Linearized plasmids digested with a restriction endonuclease, were dephosphorylated to 
prevent the plasmid from recircularizing, since dephosphorylated ends cannot be ligated 
together by DNA ligase.  
1,5 units (U) of shrimp alkaline phosphatase (rSAP) was added to the previous restriction 
endonuclease digestion reaction, and incubated at 37 °C for 30 minutes. To deactivate the 
rSAP, the sample was heated to 65 °C for 5 minutes. 
 
2.13 Transformation of Plasmids into Chemically-Competent E. 
coli 
 
Following the manipulation of plasmids, the DNA was transformed into chemically 
competent E. coli cells for storage and future work. Bacterial cells (DH5α or MFDpir -Table 
1) were prepared to enable DNA uptake by transformation according to a method described 
by Inoue, Nojima and Okayama (57) and stored at -75°C by Nicole Podnecky.  
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A 200 µL vial of chemically-competent cells was slowly thawed on ice, then added to the 
plasmid-containing solution to a total volume of 210-220 µL. The sample was incubated on 
ice for 30 minutes, then heat-shocked at 42 °C for 45 secs, followed by further incubation on 
ice for two minutes. To assist the bacterial cells’ recovery, super optimal broth with catabolite 
repression (S.O.C.), was added to the cells to a total volume of 1 mL, and the cells were then 
placed in a shaking incubator (150 rpm) at 37 °C for one hour. After recovery, the bacterial 
suspension was spread plated on appropriate selective media. 
All pCR®-Blunt and pGEM®-T Easy plasmid derivatives were transformed into the E. coli 
DH5-a strain, and all pDS132 or pEX6K plasmid derivatives were transformed into the E.coli 
MFDpir conjugation strain, since the pir gene is required for maintenance of plasmids 
carrying the R6K origin of replication. Diaminopimelic adic (DAP) was added to the S.O.C. 
at a concentration of 400 µg/mL, for the transformations into the MFDpir strain. 
For the DH5-a strain, 100 µL of the transformation reaction was plated on one plate, and the 
rest of the reaction was plated on a second plate, whereas the entire reaction was plated on 
one plate for the MFDpir strain. This was due to the lower competence and growth capacity 
of the MFDpir strain. All plates were incubated over night at 37 °C, but some were left to 
incubate for another night when no transformants had initially grown. After every successful 
plasmid transformation, four single isolated colonies were picked from the plate and 
inoculated into selective liquid overnight cultures. A portion of a liquid culture was used to 
make glycerol freeze stocks (Section 2.3.4), and the rest was typically used for plasmid 
isolation (Section 2.5). 
 
2.14 Conjugation (Bi-parental Mating) 
 
Plasmids containing an oriT can be transferred to other strains by conjugation from the E. coli 
MFDpir conjugation donor strain. This strain carries the conjugation machinery RP4, and can 
therefore serve as a plasmid donor. In addition, the MFDpir strain is a DAP auxotroph and 
cannot produce DAP itself. The absence of DAP in the media can therefore be used as a 
counter-selection, as the MFDpir strain would not be able to survive. 
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A liquid culture of MFDpir containing a conjugagive plasmid, and the recipient strain, were 
grown overnight. 1 mL of each culture was put in separate sterile tubes and centrifuged at 
12.000 rpm for 30 secs. The supernatant was discarded and the cells were resuspended in 1 
mL of 10 mM MgSO4 before centrifugation for 30 secs to wash the cells. This wash step was 
repeated two times, before resuspending the cells in 200 µL MgSO4. 50 µL of both the 
MFDpir donor and the recipient strain was mixed and spotted on a LB DAP (400 µg/mL) 
plate that had been preheated to 37 °C. Also, 30 µL of both the “parent strains” (donor and 
recipient) was spotted on the same plate as controls. After incubation overnight at 37 °C, the 
three cell spots were scraped from the plate using a sterile plastic loop. The cells were 
resuspended in 500 µL of LB and washed with 1 mL of LB three times to remove any 
residual DAP. After resuspending in 1 mL LB, the three cell solutions were spread on 
individual plates with selective pressure according to the plasmid-encoded resistance gene(s) 
(see Table A 1 in Attachments for table of chemicals/drugs added to media). After incubation 
overnight at 37 °C, only the mated cells that received the plasmid would be able to survive the 
selective pressure. The MFDpir strain will not survive without presence of DAP, which is not 
added to the selective plates, and the recipient strain is lacking the AMR to survive the 
selection. 
 
2.15 Antimicrobial Susceptibility Testing 
 
A microbroth dilution assay (IC90) was used to determine the susceptibility of the ECO-SENS 
strains (Table 1) to kanamycin. The strains of interest were struck from a glycerol freeze stock 
onto an LB plate. After incubation overnight at 37°C, 0,5 McFarlands (~1,5x108 cells) were 
prepared by suspending the bacteria in 0,85% sterile saline. The 0,5 McFarland solutions 
were diluted 1:1000 (5 µL:5 mL) in Mueller Hinton Broth (MHB). A 96 well plate was filled 




Figure 7: Amount of MHB added to the 96-well plate in a 2-fold IC90 set up. 
 
Antimicrobial working stocks were mixed in MHB to double the highest concentration tested. 
200 µL of the antimicrobial working stock was added in column 2. Using a multi-channel 
pipette, 100 µL of the antimicrobial was transferred from column 2 to column 3, where the 
antimicrobial was mixed (by pipetting up and down 15 times) with the MHB already added to 
column 3. 100 µL was then transferred from column 3 to column 4, mixed, and so on until 
column 11. 100 µL was taken out from column 11 and discarded after mixing. 
One bacterial strain was added per row, across columns 1-11. The ATCC 25922 strain was 
added to every plate as the quality control strain, to ensure the antimicrobial stocks used were 
at the correct concentration. Column 12 served as a negative control, with no antimicrobial 
and no bacteria added. Column 1 served as a positive control, with only MHB and bacteria 
added. Rows A and H were not used due to an increased risk of evaporation from these wells. 
After incubation in a shaking incubator at 37 °C and 700 rpm for 18 hours, the optical density 
at 600 nm (OD600) was measured by a plate reader. To determine the drug concentration 
which inhibited 90% of the growth (IC90), the OD600 value of a sample was compared to the 
OD600 value of a positive control, according to the following equation: 




The final IC90 value was the lowest antimicrobial concentration at which ≥ 90% inhibition 




3 Chapter 3: Experimental Results and Discussion 
 
HGR is a valuable tool to manipulate the genome of bacterial strains, as described in Section 
1.6. Using HGR, specific genetic elements are introduced and replace a strain’s original 
genomic target. Genetic elements to introduce could for instance be genes that contain AMR-
causing mutations, and then by comparing the antimicrobial susceptibility of the original to 
the engineered strains, the effect of the mutations can be evaluated. Conversely, the genetic 
element could be a WT gene, and HGR can be used to repair, or replace, a mutated genomic 
target. With either approach, HGR enables the evaluation of effects caused by specific 
mutation(s). The aim of this project was to develop an HGR approach to introduce or repair 
defined mutations in the ciprofloxacin drug target genes, gyrA and parC of clinical E. coli 
isolates.  
 
3.1 A HGR Approach to Introduce or Repair gyrA and parC 
Mutations 
 
We outlined an approach to design HGR constructs of gyrA/parC containing the gyrA(S83L 
A119E) or parC(G78D) mutations from the K56-2 CIPR strain, and replace the WT gyrA and parC 
genes in the K56-70 and K56-78 WT strains (See Figure 8 for illustration of the general 
outline in our HGR approach). The effects of these mutations could be evaluated by 
antimicrobial susceptibility testing. Changes in antimicrobial susceptibilities and potential 
collateral changes between the engineered mutants and the selected laboratory-mutants K56-
70 CIPR and K56-78 CIPR, could then be compared. We also planned a similar approach to 
repair the specific point mutations in K56-2 CIPR, by replacing the mutated gyrA and parC 
genes with HGR constructs of the K56-2 WT gyrA/parC. This would allow us to determine if 
CIP resistance and the collateral susceptibility effects seen in K56-2 CIPR are indeed caused 




Figure 8: Flow chart of general outline in HGR approach. 
 
 
3.2 Cloning and Troubleshooting 
 
 
3.2.1 Building Homologous Gene Replacement Constructs 
 
3.2.1.1 Primer Design for gyrA and parC regions 
 
Our initial goal was to design single gyrA and parC constructs that were suitable for HGR 
across multiple strains. We used Sequencher software to compare DNA sequences of the gyrA 
and parC gene regions in the K56-2, K56-70 and K56-78 strains (Figure 9). A consensus 
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sequence, representing the most frequent nucleotide at each position, was generated and we 
identified many differences between the strains. The K56-78 in particular had many mutations 
in the gyrA gene (blue dots in panel A of Figure 9), but mutations that we observed in the 
gyrA and parC genes were synonymous (did not change the amino acid sequence of these 
proteins), with the exception of the S83L and A119E mutations in gyrA and the G78D 
mutation in parC of the K56-2 CIP strain.  
 
 
Figure 9: Sequence comparison between gyrA and parC genes from K56-70 WT, K56-78 WT, 
K56-2 CIPR and MG1655. (A) gyrA(S83L A119E) and (B) parC(G78D) mutations in K56-2 CIPR are marked in 
red. The consensus sequence of the 3 strains is represented by the blue checkered bar. Yellow, green 
and blue dots represent sites of variation between the strains as compared to the consensus 
sequence. Regions conserved across all three strains are marked in pink and PCR primers that were 
designed are shown in black.  
 
In order to preserve the sequence of each strain, we had to build strain-specific HGR 
constructs. We identified conserved regions for all the strains, and primers were designed 
within the conserved regions so that the same primer set could be used to amplify the HGR 
construct for all of the strains. We designed primers to amplify large regions of gyrA and 
parC (#326 & #327 and #328 & #329, respectively) to serve as the HGR construct backbone. 
We also designed primers to amplify a short region of gyrA and parC that contained only the 
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mutation(s) of interest (#324 & #325 and #332 & #333, respectively), which would be used to 
introduce the mutations into each strain-specific HGR construct.  
All primers (oligonucleotides) are listed in Table A 3 in Attachments. 
 
3.2.1.2 PCR Amplification and Zero Blunt® PCR Cloning of gyrA and parC 
 
Portions of the gyrA and parC genes from our selected strains were cloned into the PCR Blunt 
plasmid vector. First, genomic DNA was isolated in duplicate from the K56-2 CIPR, K56-2 
WT, K56-70 WT and K56-78 WT ECO-SENS strains, resulting in DNA concentrations 
between 88,16 and 213,17 ng/µL. The duplicate with the highest DNA concentration was 
used to PCR amplify the gyrA and parC genes from the genomic DNA (Section 2.8). Primers 
#326 & #327 and #328 & #329 were used for this purpose. The size and purity of the 
resulting gyrA (1321 bp) and parC (1772 bp) PCR products were analyzed by gel 
electrophoresis (Figure 10), see Section 2.9. 
 
Figure 10: Image of gyrA and parC genes. (1% agarose gel.) Lane descriptions. 1: gyrA from K56-
2 CIPR, 2: gyrA from K56-70 WT, 3: gyrA from K56-78 WT, 4: parC from K56-2 CIPR, 5: parC from 




The PCR products from each strain looked correct both in size and that no additional bands 
were present. Each DNA band were excised from the agarose gel, and the DNA was extracted 
using the QIAquick Gel Extraction Kit. This yielded blunt-ended DNA products with 
concentrations between 25,28 and 55,2 ng/µL, appropriate for ligation into the pCR®-Blunt 
plasmid vector (Section 2.12.1). See Figure 4 for plasmid map of pCR-Blunt. 
The gyrA and parC PCR products from the K56-2 CIPR, K56-2 WT, K56-70 WT and K56-78 
WT strains, were ligated into the pCR®-Blunt plasmid. Transformation of the ligations 
resulted in pCR-Blunt-gyrA and pCR-Blunt-parC DH5-a transformants that grew on LB 
kanamycin 50 µg/mL (KM50) plates (see Section 2.13). Four single colonies from each 
ligation were grown in liquid culture (LB KM50) and glycerol freeze stocks were made. 
Plasmid DNA was isolated from these cultures (Section 2.5), resulting in DNA yields 
between 140,7 and 357,9 ng/µL.  
Correct and single insertion of the gyrA and parC segments, as well as the orientation of the 
insert, were investigated by endonuclease digestion of the plasmids. The pCR-Blunt-gyrA and 
pCR-Blunt-parC plasmids were cut with the restriction endonucleases SacI and EcoRV, 
respectively (Section 2.7). The gyrA and parC segments could have been inserted in one of 
two ways, resulting in different fragment sizes. For SacI digestion, expected sizes were either 
4392 bp + 441 bp (orientation #1), or 3876 bp + 966 bp (orientation #2). For EcoRV, the 
expected fragment sizes were either 4516 bp + 669 bp (orientation #1) or 4149 bp + 1135 bp 
(orientation #2). Fragments of 3512 bp in size indicated an empty pCR®-Blunt vector.  
The pCR-Blunt-gyrA and pCR-Blunt-parC plasmid digestions were consistent with the 
expected fragment sizes and both orientations were observed (Figure 11) with the exception 
of pCR-Blunt-parC-K56-2-WT clone #1 and #3, where EcoRV-digestion did not result in the 
expected fragment sizes (Figure A 2 in Attachments). The plasmids pSV-1 to pSV-16 were 





Figure 11: Confirmation of pCR-Blunt-gyrA and pCR-Blunt-parC plasmids. 
Gel images of pCR-Blunt-gyrA and pCR-Blunt-parC plasmids with gene inserts rom K56-2 CIPR, K56-
70 WT and K56-78 WT, after digestion with SacI (plasmid w/gyrA) and EcoRV (plasmid w/parC) on a 
1% agarose gel. All digests were consistent with expected fragment sizes. Lane descriptions. 1: 
pCR-Blunt-K56-70-WT-gyrA clone #1 orientation 1. 2: pCR-Blunt-K56-70-WT-gyrA clone #2, 
orientation 2. 7, 8: pCR-Blunt-K56-2-CIPR-gyrA(S83L A119E) clone #3 and #4, orientation 2. 11: pCR-
Blunt-K56-78-WT-gyrA clone #3, orientation 2. 12: pCR-Blunt-K56-78-WT-gyrA #4, orientation 1. 13, 
14: pCR-Blunt-K56-2-CIPR-parC(G78D) clone #1 and #2, orientation 2. 18, 19: pCR-Blunt-K56-70-WT-
parC clone #2 and #3, orientation 2. 22, 24: pCR-Blunt-K56-78-WT-parC clone #2 and #4, orientation 
2. SL; Smart Ladder.  
 
To further test the plasmids, pSV-1 to pSV-16 were cut with the restriction endonuclease 
EcoRI. EcoRI should cut the pCR-Blunt plasmid within the multiple cloning site (Figure 4, 
plasmid map), but not cut the gyrA and parC inserts. The expected fragment sizes after the 
digest were 3500 bp + 1333 bp for pCR-Blunt-gyrA, and 3500 bp + 1784 bp for pCR-Blunt-
parC. All digests were consistent with the expected fragment sizes. See Figure 12 for gel 





Figure 12: Image of pSV-1 to pSV-11 plasmids with gyrA/parC gene inserts From K56-2 CIPR, 
K56-70 WT and K56-78 WT, after digestion with EcoRI. 1% agarose gel. All digests were consistent 
with expected fragment sizes. SL; Smart Ladder. 
 
All of the EcoRI digestions matched the expected band sizes. This concluded the cloning of 
the HGR constructs with the WT gyrA or parC from K56-2 (pSV-13 and pSV-15, 
respectively). These constructs would later be used to repair the mutated gyrA and parC 
genomic targets in K56-2 CIPR strain. For the remaining constructs it was then necessary to 
introduce the gyrA and parC mutations from K56-2 CIPR.  
 
3.2.1.3 Introduction of gyrA and parC Point Mutations by ITAC 
 
Small DNA fragments containing the gyrA(S83L A119E) or parC(G78D) from K56-2 CIPR were 
cloned by ITAC into pSV-2, pSV-3, pSV-5 and pSV-7, replacing the corresponding portion 
of gyrA and parC in the WT constructs. ITAC is a very rapid method of molecular cloning 
(see Section 2.12.3) that combines DNA fragments with overlapping or homologous ends. 
The resulting plasmid can be transformed into chemically competent cells after the one-hour 
reaction time and filtration step. The DNA fragments to be cloned by ITAC were prepared by 
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PCR amplification to add overlapping regions to the fragments ends using primers that 
contained the complementary regions. 
The pSV-2, pSV-3, pSV-5 and pSV-7 plasmids were diluted to 1 ng/µL in sterile Milli-Q 
water. The plasmid backbones as well as portions of the gyrA/parC WT genes were PCR 
amplified in duplicate, using primers #330 #331 for pSV-2 and pSV-3 and #334 #335 for 
pSV-5 and pSV-7. These primers were designed with a region of 30 bases that matched the 
sequence surrounding the gyrA(S83L A119E) and parC(G78D) mutations in K56-2 CIPR, which was 
suitable for cloning by ITAC. After PCR amplification, the products were digested with DpnI. 
DpnI has a very frequently found recognition site, but will only digest methylated DNA (in 
this case the original plasmids that were methylated by methylase enzymes in DH5α). This 
allowed for separation of the template DNA from the PCR products on the agarose gel. The 
samples were analyzed by electrophoresis, and the correct sized bands (4477 bp for pSV-2 
and pSV-3, and 5172 bp for pSV-5 and pSV-7) were extracted from the gel, yielding DNA 
concentrations between 17,1 ng/µL and 70,7 ng/µL. 
Regions where the gyrA(S83L A119E) and parC(G78D) mutation were located in K56-2 CIPR, were 
amplified in duplicate from pSV-11 (primers #324 #325) and pSV-9 (primers #332 #333). 
This resulted in PCR products of 356 bp and 112 bp in size that were extracted from the gel 
after electrophoresis, yielding DNA concentrations of 48,6 and 24,9 ng/µL, respectively.  
See Figure A 4, Figure A 5, Figure A 6, Figure A 7 and Figure A 8 in Attachments for gel 
images after electrophoresis of the plasmid backbone and mutation region PCR products. 
ITAC was used to clone the PCR amplified pSV-2 and pSV-3 with the gyrA mutation region 
from pSV-11, and the PCR amplified pSV-5 and pSV-7 with the parC mutation region from 
pSV-9, where 2,5 µL of each fragment to ligate were added to the ITAC reactions. This 
resulted in four gene constructs with gyrA or parC from either K56-70 WT or K56-78 WT, 
containing the gyrA or parC mutation(s) from K56-2 CIPR. The reactions were then 
transformed into DH5-a cells and plated onto LB KM50 plates. Four isolated transformants 
were stored in glycerol freeze stocks and plasmid DNA was isolated, resulting in DNA yields 
from 92,96 to 301,7 ng/µL. The plasmids were then digested with restriction endonuclease 
EcoRI to identify whether the plasmid vectors where intact and the correct size. The expected 
digest sizes were 3500 bp + 1333 bp for PCR-Blunt-gyrA(S83L A119E) and 3508 bp + 1784 bp 
for pCR-Blunt-parC(G78D). EcoRI digestion resulted in fragments of expected sizes, however 
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half of the PCR-Blunt-parC(G78D) plasmids had additional unexpected bands, but at least one 
of the tested candidate plasmids looked correct for each plasmid that was cloned (Figure 13). 
The plasmids pSV-19 to pSV-22 and were selected for further work. 
 
 
Figure 13: Image of pSV-19 to pSV-22 after EcoRI digest. 1% agarose gel. Lane description: 2-4: 
pCR-Blunt-K56-70-WT-gyrA(S83L A119E) clone #2-4. 6-8: pCR-Blunt-K56-78-WT-gyrA(S83L A119E) clone #2-
4. 9: pCR-Blunt-K56-70-WT-parC(G78D) clone #1. 11: pCR-Blunt-K56-78-WT-parC(G78D) clone #1. SL; 
Smart Ladder. 
 
To confirm that the desired gyrA and parC mutations had been successfully cloned into the 
WT constructs, each of these four plasmids and the K56-2 WT containing plasmids, pSV-13 
and pSV-15, were submitted for sequencing (see Section 2.11). The general plasmid 
sequencing primers M13 (#300 #301) were used, in addition to internal sequencing primers 
#324 for pSV-13, pSV-19 and pSV-20, and #333 for pSV-15, pSV-21 and pSV-22 to ensure 
complete coverage. Using the Sequencher software we aligned the resulting HGR construct 
sequences to the respective strain WT sequences.  
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For plasmids pSV-13, pSV-19 and pSV-20, the HGR constructs had the expected DNA 
sequence (Figure A 13 in Attachments). The sequencing to confirm the gene constructs in the 
pSV-15, pSV-21 and pSV-22 plasmids did not cover the entire construct. However, based on 
the initial comparison, we suspected that pSV-22 contained the parC gene region from K56-
70 WT and not K56-78 WT. Plasmids pSV-15, pSV-21 and pSV-22 where sequenced again, 
using primers #300, #301 and #332, which allowed for coverage over the entire construct 
(Figure A 14). We confirmed the sequences of the constructs in pSV-15 and pSV-21. The 
sequencing results revealed that the construct in pSV-22 was indeed the gene background 
from K56-70 WT parC and not from K56-78 WT parC, but the construct did contain the 
desired parC mutation. This was most likely due to a personal error during ligation of the 
parC gene into pCR-Blunt. 
 
3.2.1.4 Repeating pCR-Blunt-K56-78-WT-parC(G78D) Construct 
 
Striving to detect where the K56-70 WT parC fragment was introduced into the construction 
of the K56-78 parC HGR construct, pSV-8 was sequenced, which confirmed the correct gene 
background from K56-78 WT parC. From this point the ITAC assembly was repeated to 
introduce the parC mutation; the pCR-Blunt backbone and parts of the parC construct was 
amplified from pSV-8 (primers #334 #335) as well as the parC(G78D) region in pSV-9 (primers 
#332 #333). The pSV-8 derived PCR product was digested with DpnI and the correct sized 
PCR products (5172 bp and 112 bp) were extracted from the gel yielding DNA concentrations 
of 14,0 ng/µL for pSV-8 and 14,3 ng/µL for pSV-9. See Figure A 9 in Attachments for gel 
image of pSV-8 PCR product. Then the ITAC reaction and transformation was repeated and 
resulted in DH5-a transformants on LB KM50 plates. Four single colonies were selected, 
isolated in liquid LB KM50 and stored in glycerol freeze stocks. Plasmid isolation resulted in 
DNA yields of 267,3 to 326,7 ng/µL, and were digested with EcoRI. Expected band sizes of 
3508 bp + 1784 bp were observed on a gel in three of the four candidates (Figure 14). pSV-23 
was chosen, but DNA sequencing of pSV-23 (primers #300, #301, #332, and #333) showed 





Figure 14: Image of pSV-23 after EcoRI digest. 1% agarose gel. Lane description: 1, 3, 4: pCR-
Blunt-K56-78-WT-parC(G78D) clone #1, #3, #4. SL; Smart Ladder. 
 
We confirmed the sequences of the K56-78 WT parC constructs in pSV-17 and pSV-18 
(primers #300, #301, #332, and #333). There were no mutations present in these constructs, 
so the single mutation observed in pSV-23 was likely an error introduced during PCR 
amplification. pSV-18 was used as the backbone for the third attempt to construct the pCR-
Blunt-K56-78-WT-parC(G78D). PCR amplification of the plasmid backbone from pSV-18 was 
performed as before (primers #334 #335). The PCR product was digested with DpnI and the 
expected band size (5172 bp) was visualized on an agarose gel. Gel extraction yielded a DNA 
concentration of 40,6 ng/µL.  
This PCR product and the parC-mutation region previously amplified from pSV-9, were 
cloned by ITAC assembly and transformed into DH5-a. Four transformants from the LB 
KM50 plate were isolated and stored in glycerol freeze stocks. The plasmid DNA was 
extracted, which yielded concentrations between 84,5 and 270,9 ng/µL. Restriction fragment 
analysis by EcoRI digestion resulted in expected fragment sizes (3508 bp + 1784) for all four 
candidates. The plasmid with the highest yield, pSV-24 was therefore chosen for further 
 
52 
analysis. DNA sequencing of pSV-24 with primers #300, #301, #332, and #333 showed that 
construct had the correct K56-78 parC region sequence with the desired parC(G78D) mutation 
(Figure A 14 in Attachments).  
This concluded the cloning of pSV-19, pSV-20, pSV-21, and pSV-24, which contained the 
HGR constructs for the gyrA(S83L A119E) and parC(G78D) mutations.  
 
3.2.2 Cloning gyrA and parC Constructs into pDS132 by ITAC 
 
In order to use the HGR constructs to introduce or repair mutations to gyrA and parC in the 
ECO-SENS strains, the constructs had to be moved from pSV-13, pSV-15, pSV-19, pSV-20, 
pSV-21, and pSV-24, into an integrative plasmid. The conjugative plasmid pDS132 was 
considered suitable for this purpose, since it is non-replicative in the target strains (R6K 
origin of replication), has selectable (chloramphenicol resistance, cat) and counter-selectable 
(sucrose intolerance, sacB) markers. (Figure 15). 
 




Our initial strategy was to subclone the HGR constructs into pDS132, using the ITAC 
method. Plasmid DNA was isolated for pDS132 and pSV-13, pSV-15, pSV-19, pSV-20, pSV-
21, and pSV-24, yielding concentrations of 295,8 ng/µL and between 106,4 and 329,7 ng/µL, 
respectively. The HGR constructs were amplified from each plasmid by PCR and overlapping 
regions complimentary to the pDS132 vector insertion site were added using primers #348 
and #349. The pDS132 vector was linearized by endonuclease digestion with XbaI in four 
reactions digesting 800 ng of pDS132 each. The digested plasmid was then treated with rSAP, 
to dephosphorylate the ends of the linearized plasmid, preventing it from recircularizing (see 
Section 2.12.4.1). The PCR fragments and linearized pDS132 were analyzed by 
electrophoresis (Figure 16 and Figure 17). Correct sized DNA fragments (gyrA constructs: 
1394 bp, parC constructs: 1845 bp, and pDS132: 5286 bp) were excised from the gel and the 
DNA was extracted. The resulting DNA yields of the gyrA constructs were between 70,3 and 
99,7 ng/µL and from 23,4 to 33,8 ng/µL for the parC constructs. For pDS132, the four 
resulting gel bands where pooled and the DNA was extracted using one single column. This 
resulted in a DNA concentration of 9,4 ng/µL.  
 
Figure 16: Image of PCR products from plasmids pSV-13, pSV-19 and pSV-20, and pDS132 after 
digestion with XbaI. 1% agarose gel. Lane description: 1, 2: PCR products of gene construct from 
pSV-13. 3, 4: PCR products of gene construct from pSV-19. 5, 6: PCR products of gene construct 





Figure 17: Image of PCR products from plasmids pSV-15, pSV-21 and pSV-24, and pDS132 after 
digestion with XbaI. 1% agarose gel. Lane descriptions. 1: PCR product of gene construct from 
pSV-15. 2: Failed PCR of gene construct from pSV-15. 3, 4: PCR products of gene construct from 
pSV-21. 5, 6: PCR products of gene construct from pSV-27. 7, 8: pDS132 digested with XbaI, parallel 
#3-4.	(-); negative (PCR master mix), SL; Smart Ladder. 
 
The ITAC method was used to assemble the HGR construct-PCR products with the 
linearized, dephosphorylated pDS132. For the gyrA constructs, 4 µL of vector DNA and 1 µL 
of insert DNA was used, and for the parC constructs, 3 µL of vector and 2 µL of insert was 
used. The ITAC reactions were then transformed into chemically competent MFDpir cells 
and spread on LB-agar plates containing DAP400 and CHL25.  
This approach was not successful, as there was no growth of MFDpir transformants, even 
after 48 hours of incubation. Failure of the ITAC reaction was most likely, so we took the 
following steps outlined below to improve the chances of successful cloning into pDS132, 
experimenting only with pSV-13 and pSV-19. 
Troubleshooting – Gel Fragment Yields 
The gel extraction of the linearized pDS132 resulted in very poor yield (9,4 ng/µL), and our 
first thought was that there was a problem with the gel extraction method, and that the low 
yields of the vector caused unsuccessful cloning. The XbaI digest and rSAP 
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dephosphorylation of pDS132 was repeated (Figure A 10 in Attachments), but this did not 
give higher yields from gel extraction (8,11 ng/µL).  
Striving to enhance the yield of the linearized plasmid, two 25 µL digestion reactions were set 
up where 4 µg of pDS132 was treated with 0,5 µL XbaI in a prolonged six-hour digestion. 
The samples were then treated with rSAP and analyzed on an agarose gel by electrophoresis 
(Figure A 11, Attachments). The correct sized DNA bands were again eluted on a single silica 
column during gel extraction. This time, the Monarch® DNA Gel Extraction Kit (NEB) was 
used. This enlarged digest and the change of gel extraction kit did not enhance DNA yield, 
which resulted in an even lower plasmid concentration of 6,6 ng/µL.  
Troubleshooting – ITAC Ratios 
Since we were not able to improve the concentration of the pDS132 vector for ITAC 
assembly, we decided to try varying the vector:insert ratios. Ideally, there should be one HGR 
construct for every vector in the ITAC reaction. Using a 1:1 volume:volume ratio, adding 2,5 
µL of both vector and insert (at different DNA concentrations) had worked well for the initial 
ITAC assemblies to construct the pSV-19, pSV-20, pSV-21 and pSV-24 plasmids, but 
optimization of this ratio could increase the likelihood of a successful cloning. In addition to a 
1:1 volume:volume ratio, ratios of 1:3, 2:3, 3:1, 4:1 and 4,5:0,5 between vector and insert 
were tried, using pDS132 linearized plasmid with concentrations from 6,6-9,4 ng/µL. In 
addition, a molecular ratio was calculated as indicated in Section 2.12.4, resulting in a 1:1,67 
volume:volume ratio. However, in each case, the following transformation into MFDpir cells 
resulted in no colonies on LB KM50 DAP400 plates. 
Troubleshooting – Plasmid Transformation 
To rule out the possibility that transformation into the MFDpir chemically competent cells 
was unsuccessful (e.g. a reduced ability to obtain a plasmid) a transformation with 5 µL of the 
uncut pDS132 vector (71,2 ng/µL), was set up. The transformation of 356 ng of uncut 
pDS132 resulted in growth of approximately 100 colonies of MFDpir transformants on LB 
CHL25 DAP400 plates, which confirmed an effective transformation protocol.  
This experiment did not determine the actual transformation efficiency of our competent cells, 
as this typically is measured by counting visible colonies after transformation of only 100 pg-
1 ng of DNA. Still, yielding only 100 colonies of MFDpir transformants after transforming 
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356 ng was considered low, compared to the expected number of 5x108 colony forming units 
per µg (CFU/µg) DNA (58). 
We could have attempted to optimize the transformation protocol to get the best possible 
efficiency from our cells (e.g. by testing several different heat shock- and recovery times 
during transformation). If that would not increase the efficiency, we could have made new 
chemically competent MFDpir cells that hopefully would be more competent. But as the 
transformation of uncut pDS132 gave growth of transformants, (suggesting that if the ITAC 
reaction was efficient, we could expect transformants), we continued to evaluate the cloning 
process. 
Troubleshooting – ITAC pDS132 Vector Fragment Concentration 
Since we only had successful cloning by ITAC when joining two DNA fragments that had 
been amplified by PCR, and after several unsuccessful attempts on cloning the fragments after 
linearizing the plasmid by digestion with XbaI, we decided to also amplify the pDS132 vector 
by PCR. The primers for pDS132 (#387 #388) were designed to add regions complementary 
to the ends of the HGR construct amplicons, functioning as the region of overlap required for 
ITAC.  
PCR amplification of pDS132 resulted in a 5137 bp PCR product (Figure A 12 in 
Attachments). Gel extraction of the correct sized-band yielded a concentration of 63,7 ng/µL. 
We set up ITAC reactions using this pDS132 PCR fragment and the HGR construct-PCR 
products from before. We expected the ITAC reaction to be successful with this enhanced 
vector concentration, but several attempts with volume:volume ratios of 1:1, 1:1,67, 1:3 and 
3:1 (vector:insert) were tested without success, as no colonies were observed on the LB 
CHL25 DAP400 plates after transformation into MFDpir. 
Troubleshooting – ITAC Reaction Efficiency 
Since our original ITAC reactions were successful in the construction of pSV-19, pSV-20, 
pSV-21 and pSV-24, we suspected a problem with our ITAC reactions. A new batch of the 
ITAC reaction mixture had been made since our first successful experiments, so we evaluated 
the efficiency of the ITAC reaction. We did this by repeating one of our previously successful 
ITAC reactions. By storing all PCR-products at -20 °C during this project, we were able to 
repeat one of the very first ITAC reactions that had been successful, and compared the results 
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with the new ITAC reagents to the previous results. An ITAC reaction to assemble the pSV-
19 plasmid was repeated. The reaction was then transformed into DH5-a, resulting in 
approximately 25 single colonies of DH5-a transformants from plating the whole 
transformation (1 mL). This was much fewer transformants than from the original reaction, 
resulting in 299 single colonies from plating 100 µL of the transformation.  
This poor result suggested that at least one step in our ITAC strategy had changed, causing 
reduced overall efficiency. Since the transformation process into DH5-a had been evaluated 
previously and was successful, the transformation was unlikely to be the issue, as the protocol 
was thoroughly followed using DH5-a cells from the same batch. The latest prepared ITAC 
buffer was likely to have been less efficient than the one previously used, and a new batch 
should have been prepared. However, due to costs and the latency to receive the necessary 
reagents, we could not test this. We determined that the purification of the ITAC reactions 
before transformation was the only step we could optimize in the ITAC protocol. 
Troubleshooting – DNA Purification Step 
According to the ITAC method, following the ITAC reaction itself, the samples were to be 
purified with sterile Milli-Q water by drop dialysis (Section 2.12.3.1). Another method to 
purify such a sample is to use a kit for general DNA fragment purification, e.g. a PCR clean-
up kit. During most DNA purification steps, some of the sample is lost. We wondered if 
during the drop dialysis filtration step we lost more of the DNA than with an alternative 
method, and that the lack of transformants was due to a loss of our sample before 
transformation. 
We compared two DNA purification methods, drop dialysis and sample purification with a 
PCR clean-up kit. The same ITAC reaction that was used to investigate ITAC efficiency 
(assembling pSV-19) was again repeated in triplicate. Of the three resulting samples, one was 
not purified, one was filtered by drop dialysis, and the last was purified using the QIAquick 
PCR Purification Kit (Qiagen, Hilden, Germany) following manufacturer’s guidelines. Each 
reaction was then transformed into chemically competent DH5-a cells and plated onto LB 
KM50 plates for 24 hours.  
The sample purified with the PCR clean-up kit yielded the fewest transformations, with only 
one colony (Table 10). The ITAC followed by drop dialysis resulted in the same amount of 
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growth as the earlier repetition (approximately 25 colonies of DH5-a transformants from the 
entire 1 mL transformation), but the transformation carried out without any purification step 
resulted in approximately 60 colonies of DH5-a transformants, the most of the three 
approaches.  
 
Table 10: Results from ITAC purification optimization. Using no filtration of ITAC products yielded 










For the PCR clean up kit, some of the DNA was either bound to the silica column and not 
released during elution, or was not initially bound to the column and the DNA was washed 
away alongside contaminants during the washing step. During the drop dialysis, DNA might 
be lost by diffusion into the water, or loss of some of the sample could occur when pipetting 
off of the filter.  
Nevertheless, the rationale for purifying the samples is to get rid of excess reaction residues, 
and clean DNA is considered optimal for the transformation process. But since we had the 
greatest success without cleanup of the ITAC reaction, we made another attempt to join the 
PCR amplified pDS132 vector and the PCR amplified HGR constructs. Again we used 
different ratios of the pDS132 vector to the construct inserts, but without any filtration step 
before transformation of the samples into MFDpir. The ratios tested were 1:1, 1:1,67, 1:3 and 





While we were able to optimize and eliminate a number of variables to improve the ITAC 
reaction and transformation procedure, our initial approach to move the gene constructs from 
pSV-13, pSV-15, pSV-19, pSV-20, pSV-21, and pSV-24 into pDS132 by ITAC, was not 
successful. See Figure 18 for illustration of the trouble shooting process and cloning attempts 
with the pDS132.  
Ultimately, the inefficiency of the ITAC could have been due to partial overlapping regions 
elsewhere in the plasmid. Deciding on a different region of overlap where the HGR constructs 
were to be inserted in pDS132, could improve the success of this method. We were unable to 
eliminate two major sources of reduced efficiency that should be further investigated: the new 
ITAC reaction buffer yielded over 100 fold fewer transformants (25 vs 2990 colonies per 1 
mL transformation in DH5-a cells) and the low efficiency of transformation into chemically-
competent MFDpir cells.  
If we were to continue attempts to move the HGR constructs into the vector by ITAC, our 
next approach would have been to produce new ITAC buffer. Amongst other cautions, 
keeping the enzymes in the ITAC buffer at cool temperatures at all times is key in order for 




Figure 18: Flow chart of attempts made to clone HGR constructs into pDS132 by ITAC. After 
several attempts to optimize the ITAC procedure, we decided to change approach. 
 
3.2.3 Molecular Cloning of gyrA and parC Constructs into pEX6K 
 
We decided to use more traditional methods to move the HGR constructs into pDS132. 
Cutting both vector and insert with one restriction endonuclease would result in compatible 
ends on the fragments that can be joined by DNA ligation.  
However, the restriction recognition sites available on pDS132 and the sites surrounding the 
HGR constructs were incompatible, meaning that no known endonucleases could cut both 
pDS132 and the inserts for ligation. The pDS132 plasmid contained only a few restriction 




An alternative approach would be to cut both the vector and insert with incompatible 
endonucleases and process the resulting ends so that both fragments have blunt ends. 
However, this approach was avoided in this project because of the low efficiencies of both the 
blunting reaction and blunt-end ligation. Instead we decided to subclone HGR constructs into 
another vector, pGEM®-T Easy (Figure 5), and to further clone them into an alternative 
conjugative plasmid, pEX6K (Figure 19), that contains compatible restriction sites with 
pGEM®-T Easy. 
 
Figure 19: Plasmid map of pEX6K (7298 bp). Properties and restriction sites used in this project are 
indicated. 
 
The HGR constructs were subcloned into the linearized pGEM®-T Easy vector, which 
contains 3´ T overhangs. For successful cloning, inserts needed to contain an extra A base in 
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the 5´ ends, a so called A-tail. Each of the six HGR construct-PCR products previously 
amplified with primers #342 and #343, were given a 5´ A-tail by incubating the samples with 
adenine and Dream Taq DNA polymerase (Section 2.12.2.1). 
The compatible HGR constructs were ligated into the pGEM®-T Easy vector (Section 2.12.2) 
and then transformed into chemically competent DH5-a. The transformations were plated on 
LB-Agar plates with AMP100, XGal50 and IPTG0,5 mM. Each of the six ligations yielded single 
white colonies, but also blue colonies that contained the empty vector. The ligation reaction 
was very efficient and white colonies were observed even when plating a 1:10 dilution of the 
transformation.  
For each ligation, four single white colonies were selected, struck for isolation on AMP100, 
XGal50 and IPTG0,5 mM plates to confirm the lack of blue color, and grown in liquid culture 
with AMP100 the following day. Isolates were stored in glycerol freeze stocks, and plasmid 
DNA was isolated from the remaining liquid culture for two of the parallels, using the 
Monarch® Plasmid Miniprep Kit (NEB). Plasmid isolation resulted in DNA concentrations 
ranging from 91,0 ng/µL to 336 ng/µL. The parallel with the highest DNA concentration was 
selected to continue work with, plasmids pSV-25 to pSV-30.  
To clone the HGR constructs from the pGEM-T Easy background into pEX6K, 1000 ng of 
DNA from the pSV-25 to pSV-30 plasmids was digested with NotI. DNA digests were then 
analyzed by electrophoresis (Figure 20). DNA was extracted from desired NotI-digested 
construct bands (gyrA constructs: 1391 bp, parC constructs: 1842 bp) yielding between 5,6 





Figure 20: Image of pSV-25 to pSV-30 after digestion with NotI  1% agarose gel. 
 Undigested plasmid: 2981 bp. Lane description. 1: pSV-25-construct. 2: pSV-26-construct. 3: pSV-
27-construct. 4: pSV-28-construct. 5: pSV-29-construct. 6: pSV-30-construct. SL; Smart Ladder. 
 
To ensure high plasmid yield, six 5 mL liquid cultures of MFDpir (LB KM50 DAP400) 
containing the pEX6K plasmid were grown overnight and plasmid DNA was extracted. The 
pEX6K DNA was extracted on a single column, which resulted in a plasmid DNA 
concentration of 213,7 ng/µL. To linearize the plasmid and make the ends compatible with 
the HGR construct inserts, the pEX6K vector was also digested with NotI. Triplicates of 800 
ng pEX6K were digested followed by dephosphorylation of the ends with rSAP. The 
linearized plasmid was not analyzed by electrophoresis as the uncut plasmid would be of 
almost the same size. The linearized plasmid was instead purified after the digestion reaction 
by using the gel extraction kit, yielding a plasmid concentration of 59,7 ng/µL. 
The NotI treated pEX6K vector and HGR constructs were fused together by ligation (Section 
2.12.4), and transformed into MFDpir before plating on LB KM50 DAP400. Tiny colonies of 
MFDpir transformants had grown after overnight incubation. Four colonies from each 
ligation were isolated by plating on LB KM50 DAP400 and grown in liquid the following day, 
before being stored in glycerol freeze stocks. Remains of the liquid cultures from two of the 
four parallels were used for plasmid isolation. Plasmid isolation of the transformants yielded 
very little plasmid DNA with concentrations ranging from 3,4-13,2 ng/µL. However for 
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pEX6K-K56-78-WT-gyrA(S83L A119E) parallel #2 (pSV-32), plasmid isolation resulted in a 
much higher DNA concentration of 298,3 ng/µL. The plasmids with the highest yield were 
chosen, pSV-31 to pSV-36. 
Because plasmid yields from pSV-31, pSV-33 to pSV-36 were so low, it was possible that the 
transformants did not contain the correct plasmid. The colonies of MFDpir transformants 
after ligation with pEX6K were tiny and we were suspicious of whether the small colony 
growth could be contamination of the plates. A clean LB KM50 DAP400 was incubated 
overnight, but nothing grew on the plate, suggesting that no contamination had occurred when 
pouring the plates.  
The ligations of the HGR constructs with pEX6K should have been repeated for pSV-31, and 
pSV-33 to pSV-36, but we decided to proceed with pSV-32 that yielded high plasmid 
concentration after isolation.  
To confirm successful ligation of the gyrA construct into pEX6K in pSV-32, the plasmid 
DNA was sequentially digested with SmaI, XhoI and a third endonuclease to confirm the 
orientation of the insertions, HindIII. The pEX6K-parC derivatives were supposed to be 
digested with CaiI. However, only pSV-32 could be digested, as the plasmid concentrations 
after isolation from MFDpir were too low to setup the DNA digestions (it would not be 
possible to visualize the DNA bands after digestion).  
Digestions with SmaI, XhoI and HindIII were setup of pSV-32, pEX6K and the pEX6K 
predecessor, pEXKm5 (Figure 21). These digestions resulted in expected fragment sizes from 
pEXKm5 (7767 bp + 11bp), but not the expected fragment sizes from pEX6K (6752 bp + 535 
bp + 11 bp). The pEX6K digest resulted in fragments of approximately 3500 bp + 2000 bp + 





Figure 21: Image of pSV-32, pEXKm5 and pEX6K after sequential digestion with SmaI, XhoI and 
HindIII. 1% agarose gel. Lane description. 1: pSV-32. 2: pEXKm5. 3: pEX6K. SL; Smart Ladder. 
 
Digestion of pSV-32 did not result in the expected fragment sizes either, and the gel image 
showed the same fragment sizes as for pEX6K, but with an additional fragment of 
approximately 1000 bp. This suggested that our insert was likely present in the pEX6K 
background, but that the pEX6K plasmid was not digesting as we expected. 
 
3.3 Conjugation of pEX6K-derivatives into ECO-SENS Strains 
 
We assumed that the K56-78-gyrA(S83L A119E) construct for HGR was correctly cloned into 
pEX6K, pSV-32. The next step was to mobilize the pSV-32 plasmid from the conjugation 
donor strain MFDpir, into the K56-WT ECO-SENS strain by conjugation.  
Liquid cultures of MFDpir containing pSV-32 and the K56-78 WT ECO-SENS were grown 
overnight, representing the donor and recipient strains, respectively. The overnight cultures of 
both donor and recipient were inoculated together (conjugation) and individually, on one LB 
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DAP400 plate (Section 2.14). After conjugation, the MFDpir donor strain, the WT ECO-SENS 
recipient strain, and the mated cells were plated on LB KM50. Only the recipient that had 
gained the plasmid with the KMR marker should grow under the selective pressure, since the 
MFDpir donor strain is DAP auxotroph, and the WT ECO-SENS recipient should not be 
KMR. However, plating of the strains on individual KM50 plates, resulted in growth of both 
the conjugated/mated cells (195 colonies) and the K56-78 WT ECO-SENS recipient (128 
colonies).  
The ECO-SENS strains used in this study are part of a pan-susceptible panel of clinical E. coli 
isolates, however, susceptibility testing of the WT ECO-SENS strains with KM had not been 
done previously in the MicroPop lab. We suspected that the K56-78 WT ECO-SENS strain 
might be resistant to KM50. 
 
3.3.1 Susceptibility Testing of WT ECO-SENS Strains 
 
A macrobroth dilution experiment was set up to determine the rough MIC of kanamycin to 
inhibit growth of K56-2 WT, K56-70 WT and K56-78 WT ECO-SENS strains. Liquid 
cultures of LB KM50, KM100, KM200, KM300 and KM400 with the three different strains 
(applied from glycrol freeze stock) were grown overnight. There was not growth in any of the 
cultures, except for K56-78 WT in LB KM50. This suggested that plates of LB KM50 lacked a 
high enough concentration of KM to prevent growth of the K56-78 WT ECO-SENS strain 
following conjugation. LB KM100 plates were prepared and the conjugation of pSV-32 
between MFDpir and the K56-78 WT ECO-SENS was repeated. Incubation on LB DAP400 
and spreading of the cells on KM100 the following day, again resulted in growth of the K56-78 
WT strain. 
We suspected that the macrobroth dilution method had not resulted in accurate MIC values, 
so we decided to determine the MIC of KM by using a more standardized microbroth dilution 
method (Section 2.15). The drug concentrations which inhibited at least 90% of the growth, 
IC90, was determined based on OD600 measurements with a plate-reader after incubation. The 
IC90 was calculated to be 2 µg/mL KM for all the WT ECO-SENS strains (K56-2, K56-70 
and K56-78), and also for the ATCC strain, which was within the expected range for the 
control strain (1-4 µg/mL, (26)). 
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Since the strains were susceptible to KM at much lower concentrations than the LB KM100 
plates, and the plates were made with same KM stock that was used in the microbroth assay, 
we suspected that a step in the conjugation method might induce KMR in the WT ECO-SENS 
strains. Experiments to evaluate the effects of the washing steps, as well as plating on DAP400, 
were set up. Liquid cultures of the K56-2, K56-70 and K56-78 WT ECO-SENS strains were 
grown in LB, and 30 µL of the cultures were directly spotted on both LB and LB DAP400 
plates (without washing with MgSO4). After 24 hours of incubation, the strains were washed 
with liquid LB according to the conjugation protocol, and the solutions were spread on KM100 
plates. This resulted in growth of all the strains, both those that were spotted on LB and those 
spotted on LB DAP400. From this result, we ruled out the possibility that the MgSO4 washing 





4 Chapter 4: Concluding Remarks and Future Aspects 
 
The aim of this project was to develop a HGR approach to generate mutants carrying defined 
AMR mutations. Specifically, we aimed to study the effect of defined point mutations known 
to cause CIP resistance. While we were able to create HGR constructs with the desired 
gyrA(S83L A119E) or parC(G78D) mutations from the K56-2 CIPR strain, we encountered a lot of 
difficulty cloning the HGR constructs into a suitable plasmid (either pDS1332 or pEX6K). 
Ultimately we were not able to generate CIPR mutants by HGR, and various aspects of the 
protocol have yet to be optimized.  
The ITAC buffer was likely to have reduced efficiency, and a new batch should be prepared. 
In addition, new chemically competent MFDpir donor cells should also be made. Further 
investigation to determine if there is a step in the plating of ECO-SENS strains that introduces 
or selects for KMR is required if KM is to be used as resistance marker on the integrative 
plasmid. Designing and developing HGR approaches requires a lot of time and effort, but 
once established, HGR is a valuable tool to evaluate effects of defined mutations.  
In the future, successful conjugation of the integrative plasmid containing the HGR 
constructs, and confirmation that the HGR constructs indeed have replaced the target 
sequence in the recipient ECO-SENS strains, will allow us to study the effects of the gyrA(S83L 
A119E) or parC(G78D) mutations. The resulting mutants can then be tested to detect changes and 
differences in antimicrobial susceptibility caused by these mutations. The K56-2 CIPR 
containing the gyrA(S83L A119E) or parC(G78D) mutations displays collateral sensitivity towards 
different antimicrobials than the K56-70 CIPR and K56-78 CIPR. It will be interesting to 
finally investigate to what extend the gyrA(S83L A119E) or parC(G78D) are responsible for 
collateral effect changes. This work will ultimately expand our understanding of collateral 
susceptibility networks, and the factors that affect them, which is of importance if treatment 
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Table A 3: Primers (oligonucleotides) used in this project. 







326	 gyrA-F	 CACAACCGACATCGAGCAC	 65,7	 64	 40	 1321	
327	 gyrA-R	 GCAACTGGGTCTGGGAGTAG	 63,7	 64	 40	 1321	
324	 gyrA-K56-2	CIP-F	 ACCGGTCAACATTGAGGAAG	 63,9	 62	 15	 356	
325	 gyrA-K56-2	CIP-R	 CCAGACGGATTTCCGTATAAC	 62,0	 62	 15	 356	
330	 pCR-Blunt-gyrA-ITAC-F	
CATCGACGGCGACTCTGCGGCGGAA	 92,2	 62	 	140	
4477		
ATGCGTTATACGGAAATCCGTCTGG	 	 	 	
331	 pCR-Blunt-gyrA-ITAC-R	
TCGCATAATCCAGATAGGAGCTCTT	 85,2	 62		 	140	
	4477	
CAGCTCTTCCTCAATGTTGACCGGT	 	 	 	
328	 parC-F	 CTATCTTGATGCCCGACGAG	 64,6	 64	 55	 1772	
329	 parC-R	 GCAAGATGACGCAGTTTCAG	 63,6	 	64	 55	 1772	
332	 parC-K56-2	CIP-F	 TACCGTCGGTGACGTACTGG	 65,9	 	64	 15	 112	
333	 parC-K56-2	CIP-R	 ACCATCAACCAGCGGATAAC	 63,7	 	64	 15		 112	
334	 pCR-Blunt-parC-ITAC-F	
TGGTCCTGATGGCGCAGCCGTTCTC	 91,0	 	64	 	160	 5172	
TTACCGTTATCCGCTGGTTGATGGT	 	 	 	
335	 pCR-Blunt-parC-ITAC-R	
AGGCACTATCGTCGTGCGGATGGTA	 87,4	 64		 	160	 5172	
TTTACCCAGTACGTCACCGACGGTA	 	 	 	
348	 pCRBlunt-Ins-ITAC-F	
AGGTATATGTGATGGGTTAAAAAGGATCG	 83	 	66	 	42/56	 1394/1845	
ATCCTCTAGCGAGCTCGGATCCACTAGTAA	 	 	 	
349	 pCRBlunt-Ins-ITAC-R	
CCGGGAGAGCTCGATATCGCATGCGGTA	 90	 66		 	42/56	 1394/1845	
CCTCTAGGCCAGTGTGATGGATATCTGC	 	 	 	
342	 pCRB-Ins-F	 CGAGCTCGGATCCACTAGTAA		 	63,2	 66	 41/54		 1357/1808	
 
A6 








89,7	 61	 154	 5137	
300	 M13-F	 GTAAAACGACGGCCAGT	 58,7	 	50	 	240	 Variable		
301	 M13-R	 AACAGCTATGACCATG	 48,6	 	50	 	240	 	Variable	
 
 
Table A 4: Restriction endonucleases and corresponding buffers.  All endonucleases and buffers 





















Figure A 2: Image of pCR-Blunt-gyrA and pCR-Blunt-parC plasmids with gene inserts from K56-2 
WT, after digestion with SacI (plasmid w/gyrA) and EcoRV (plasmid w/parC). (1% agarose gel.) 3, 4: 
pCR-Blunt-K56-2-WT-gyrA clone #3 and #4. 5, 7: Unsuccessful digest of pCR-Blunt-K56-2-WT-parC 





Figure A 3: Image of pSV-13 to pSV-16 plasmids with gyrA/parC gene inserts from K56-2 WT, 
after digestion with EcoRI. (1 % agarose gel.) The digest showed expected fragment sizes in all of the 
cases. SL; Smart Ladder. 
 
 
Figure A 4: Image of PCR products from plasmids pSV-11, pSV-2, pSV-3. (1 % agarose gel.) 
Lane descriptions. 1, 2: PCR products of gyrA(S83L A119E) from pSV-11. 5: Failed PCR K56-70-WT-
gyrA-portion from pSV-2. 6: PCR product K56-70-WT-gyrA-portion from pSV-2. 7, 8: PCR products 





Figure A 5: Image of PCR products from plasmids pSV-11, pSV-2, pSV-3. (1 % agarose gel.) 
Lane descriptions. 1, 2: PCR products of gyrA(S83L A119E) from pSV-11. 5: Failed PCR K56-70-WT-
gyrA-portion from pSV-2. 6: PCR product K56-70-WT-gyrA-portion from pSV-2. 7, 8: PCR products 
K56-78-WT-gyrA-portion from pSV-3. (-); negative (PCR master mix), SL; Smart Ladder. 
 
 
Figure A 6: Image of PCR products from plasmids pSV-5, pSV-7, and (repeated) pSV-2 (1 % 
agarose gel). Lane description: 1: PCR product K56-70-WT-parC-portion from pSV-5. 2: Failed PCR 
from pSV-5. 3, 4: Failed PCR from pSV-7. 5: PCR product K56-70-WT-gyrA-portion from pSV-2. 6: 





Figure A 7: Image of PCR products from plasmids pSV-9. (2 % agarose gel.) Lane descriptions: 
1, 2, 3: PCR product of parC(G78D) from pSV-9. (-); negative (PCR master mix), SL; Smart Ladder. 
 
 
Figure A 8: Image of PCR products from plasmids pSV-7 and pSV-9. (1 % agarose gel.) Lane 
descriptions: 1, 2: PCR products of K56-78-WT-parC-portion from pSV-7. 3, 4: PCR product of 





Figure A 9: Image of PCR products from plasmid pSV-8. (1 % agarose gel.) Lane description: 1, 




Figure A 10: Image of pDS132 after repeated digestion with XbaI. (1 % agarose gel.) Lane 





Figure A 11: Image after electrophoresis of expanded XbaI digest 4 µg plasmid and 6 hours 
incubation time. (1 % agarose gel.) Lane description: 1: XbaI-treated pDS132, parallel #1. 2: XbaI-
treated pDS132, parallel #2.  3: Uncut pDS132. SL; Smart Ladder. 
 
Figure A 12: Image of PCR products of pDS132. (1 % agarose gel.) Lane description: 1, 2: PCR 





Figure A 13: Sequence results from pSV-13, pSV-19 and pSV-20.  pCR-Blunt gyrA K56-2 WT: 
pSV-13, pCR-Blunt K56-70 gyrA mut: pSV-19, pCR-Blunt K56-78 gyrA mut: pSV-20. Analyzed with 





Figure A 14: Sequence results from pSV-15, pSV-21 and pSV-24.  pCR-Blunt parC K56-2 WT: 
pSV-15, pCR-Blunt K56-70 parC mut: pSV-21, pCR-Blunt K56-78 parC mut: pSV-24. Analyzed with 
Sequencher software. 
